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Abstract 
 
Cancer is a disease concerning the abnormal, uncontrolled growth of cells that possess a 
potential to invade and injure other parts of the body. Chemotherapy involves 
administration of drugs targeted towards the mechanisms responsible for this rapid 
division and proliferation. However, most chemotherapy drugs are non-specific, also 
causing allied toxicity to normal cells undergoing cell division.  
In this work, phytochemicals were used as anti-cancer drugs. These molecules are non-
toxic and biocompatible. However, they also display striking anti-cancer potential, which 
was explored in this thesis. In this work, epigallocatechin gallate, piperine and mangiferin 
have been explored for their anti-cancer efficacy. 
Although phytochemicals are effective agents in cancer chemotherapy, many of them 
suffer from disadvantages such as pH instability and limited bioavailability in the body. 
To address this problem, nanocarriers were designed to facilitate their increased 
bioavailability and stability inside the body. Two nanoparticle matrices were explored in 
this work; solid lipid nanoparticles and chitosan nanoparticles. Solid lipid nanoparticles 
were used as they are biocompatible, help improve drug stability and show controlled 
release. Chitosan nanoparticles are biodegradable, biocompatible and have shown 
excellent absorption properties for chemotherapeutic drugs.  
Chemotherapy mainly deals with two targeting approaches; active and passive. While 
passive targeting relies on the characteristics of the tumour for effective therapy, active 
targeting involves attachment of ligands on the nanocarrier for more specific targeting. 
Both the targeting approaches have been explored in this work. In addition, two targeting 
ligands were used in this work; bombesin and mannose, which are specific for factors 
overexpressed in cancer. 
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In summary, this thesis involves the design and fabrication of nanocarriers in order to 
increase the anti-cancer efficacy of phytochemicals, utilising different targeting 
approaches, matrix components and targeting ligands. The anti-cancer efficacy was 
evaluated by in-vitro cytotoxicity studies and in-vivo animal studies. The results validate 
the increased anti-cancer efficacy provided by the encapsulation of the drugs within 
nanocarrier systems thus offering encouraging, novel possibilities in the field of cancer 
therapy.   
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1.1. Cancer 
Cancer remains one of the world’s most crippling diseases, accounting for about 1 in 
every 7 deaths worldwide – more than HIV/AIDS, tuberculosis, and malaria combined[1]. 
It persists as an unsolved enigma for modern medicine, a cure for which has been sought 
since times immemorial. The word 'cancer' is derived from the Greek word for crab 
(karkinos), indicating the crab-claw like patterns of veins surrounding the tumour. 
Cancerous tissues are characterized by the abnormal growth of cells beyond their usual 
boundaries invading adjoining parts of the body and/or spreading to other organs[2]. 
Lung, prostate, colorectal, stomach and liver cancers are the most common types of 
cancer in men, while breast, colorectal, lung, cervix and stomach cancers are most 
common among women[3]. Although cancer-related mortality has decreased owing to 
better understanding of tumour biology and improved diagnostic devices and treatments, 
further advances in this field are necessary to understand the basis of disease progression, 
which will in turn lead to better therapy[4]. 
1.2. Common causes of cancer 
Cancer involves the irregular and abnormal growth of cells, perpetuating beyond their 
usual lifespan. This diseased condition can be triggered by a number of factors, with the 
most well-known being excessive smoking and use of tobacco, exposure to carcinogens, 
inadequate diet and physical activity, exposure to radiation, overall genetics, viral and 
other infections[3]. However, other factors such as the sex and age of the patient also 
influence the development of certain cancers[5].    
1.3.  Conventional approaches to combat cancer 
Current approaches for cancer treatment include surgery, chemotherapy, radiation 
therapy, immuno-therapy and gene therapy, as outlined in the following sections: 
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1.3.1. Surgery 
Surgery is the preferred method for the excision of solid tumours which are mostly 
contained to one area[6]. Excision can be complete or partial (debulking), depending on 
the magnitude of expansion of the cancerous tissue, wherein complete removal is 
attempted when the tumour is restricted to one area or organ while debulking is carried 
out when complete resection might damage an organ or functioning of the body as a 
whole[7]. While surgical resection is often a straightforward and plausible line of 
treatment, it suffers from the disadvantage of not promising complete removal of 
cancerous tissue in cases where metastasis may have taken place, but is yet dormant or 
undetected[8]. It also cannot be used for treatment of leukemias. 
1.3.2. Radiation therapy 
Radiation therapy uses high energy radiations such as gamma rays and X-rays to damage 
the DNA in cancerous cells[9]. It is of two types, external beam therapy and internal 
radiation therapy. External beam therapy involves the use of a linear accelerator for the 
production of X-rays. Internal radiation involves the implantation of a solid or liquid 
radioactive source inside the body for the emission of radiations. 
1.3.3. Chemotherapy  
Chemotherapy involves the administration of an anti-cancer drug (or multiple drugs) as a 
part of a regimen for either curative or palliative treatment[10]. It can be used as a 
neoadjuvant, wherein chemotherapeutics are administered before radiation therapy or 
surgery to reduce the tumour volume or sensitize it for more efficient therapy[8]. It is also 
used in tandem with other procedures as an adjuvant in a combinatorial chemotherapeutic 
regimen[11]. 
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1.3.4. Immunotherapy 
Cancer immunotherapy involves stimulating the immune system through the active or 
passive targeting against tumour cells[12]. It uses genetically modified cells and viral 
particles to stimulate the immune system to destroy cancer cells. Tumour cells express 
tumour-associated antigens (TAAs) which can be attacked by the immune system[13]. 
Active immunotherapy helps the immune system to better detect the TAAs and hence 
assist in their removal. In passive immunotherapy, monoclonal antibodies, lymphocytes 
and cytokines are used to enhance anti-tumour responses.  
1.3.5. Gene therapy 
Gene therapy involves the use of genes (in-vitro or in-vivo) to manipulate cancer 
cells[14]. However, ineffective delivery of the therapeutic gene to the target cells and 
multiple precautions to be taken to ensure the therapeutic gene does not integrate into 
unwanted cells, are a few challenges that gene therapy has to circumvent[15].  
1.4. Chemotherapy 
Chemotherapy is the use of anti-cancer drugs to destroy cancer cells, alone or in 
combination with other drugs and sensitizers(As mentioned in Section 1.3)[16]. It mainly 
deals with targeting the mechanisms responsible for conferring immortality to cancer 
cells. The main types of chemotherapeutic drugs used are as follows[1]: 
1.4.1.  Alkylating agents 
This class includes alkyl group containing synthetic compounds interfering in different 
phases of the tumour cell division process, preventing it from further replication. The 
alkyl groups react to form irreversible covalent linkages with the various components of 
the genetic assembly, such as DNA, RNA or proteins, halting cell division and hence 
proliferation[17]. They do suffer from the disadvantage of non-specificity wherein 
replicating non-cancerous cells may also be damaged[18]. However, defective DNA 
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repair mechanisms in cancer cells may lead to higher mortality rates in comparison to 
normal cells. Cisplatin, oxaliplatin and cyclophosphamide are common examples of 
alkylating agents. 
1.4.2. Anti-metabolites 
Anti-metabolites are modified analogs of purines, pyrimidines, nucleotides and 
nucleosides, which are components of the genetic assembly. The similarity of these 
analogs to genetic components causes them to be picked up during DNA or RNA strand 
synthesis. However irregularity in the strand structure during assimilation of these altered 
elements in DNA/RNA strand creates problems in the recoiling and coiling process 
during cell division which results in effective cytostatis[19]. Examples include 
gemcitabine, 5-fluoro uracil and methotrexate. 
1.4.3. Anti-tumour antibiotics 
Anti-tumour antibiotics are fermentation products of microbial cultures which are used in 
cancer therapeutics. They work by varied mechanisms. Actinomycin and mithromycin 
bind to the DNA and inhibit the DNA-dependent RNA synthesis while the anthracyclines 
(doxorubicin and daunorubicin) intercalate between base pairs. Bleomycin causes DNA 
strand scission whereas mitomycin C carries out DNA alkylation. The common 
mechanism of action throughout these agents is their reaction with DNA to interfere in 
the DNA replication and division process[20].      
1.4.4. Topoisomerase inhibitors 
Topoisomerases are enzymes necessary for the supercoiling and relaxation of DNA 
strands during the process of cell division. Topoisomerase inhibitors interfere with the 
functioning of these enzymes[21,22]. They are classified depending on the enzyme they 
inhibit as Topoisomerase I inhibitors, such as irinotecan and topotecan and 
Topoisomerase II inhibitors such as etoposide and daunorubicin.       
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1.4.5. Mitotic inhibitors 
These agents commonly act by interrupting cell mitosis through the inhibition of 
microtubule polymerization which is an indispensable step during cell division[23]. They 
are generally derived from plant alkaloids. Common examples include paclitaxel, 
docetaxel, vinblastine and vincristine. 
1.4.6. Corticosteroids 
Corticosteroids are primarily cholesterol-derived hormones of the adrenal cortex. Their 
mechanism of action involves multiple signalling processes to induce cell apoptosis in 
tumour cells[24]. Common examples include dexamethasone and prednisone.  
1.5. Problems with current cancer chemotherapy 
Although these enlisted chemotherapeutic drugs have been effective via various 
mechanisms against tumour tissue, there are a few drawbacks associated with their use 
which are mentioned in the following section. 
1.5.1. Non-specificity 
Chemotherapy strategies kill cells by targeting important pathways in rapid cell divisions 
characteristic of tumourous cells. However, as these therapies lack specificity, they also 
affect cellular processes in normal cells undergoing cell division, thus causing allied non-
specific cytotoxicity[25]. Many singular therapies involving one chemotherapeutic drug 
therefore have to be co-administered with agents to prevent or alleviate associated non-
specific cytotoxicity[26]. This causes overburdening of the amount of foreign substances 
increasing the chances of the reticulo-endothelial system to eliminate the therapeutic 
agent[27].  
1.5.2. Multi-drug resistance 
Development of multi-drug resistance in cancer cells is one of the leading causes for 
failure of cancer chemotherapy. Resistance can be effected by numerous mechanisms 
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such as increased drug efflux, activation of DNA repair mechanisms, produce detoxifying 
systems and evasion of drug-induced apoptosis[28]. Multi-drug resistance eventually 
causes an increase in drug dosages for beneficial therapy as the cells do not take up the 
drug in the required amounts. Also, this can increase dose-dependent toxicity at other 
sites.  
1.5.3. Biological barriers 
The human body contains a number of biological and biophysical barriers such as the 
blood brain barrier (BBB), cells of the reticulo-endothelial system (RES) and endothelial 
cell junctions. The BBB is comprised of tight junctions between epithelial cells, halting 
extravasation of chemotherapeutic agents. The BBB also has high specificity in the size 
and solubility characteristics of the molecules passing through it. The endothelial cells 
and cells of the RES act as immunological barriers by effectively hoarding therapeutic 
agents[29]. This causes an inability to deliver therapeutic drugs at the target site and 
increased drug dosages. 
1.5.4. In-vivo degradation  
The metabolic enzymes within the human body, such as proteases, lipases, hydrolases 
etc. can rapidly degrade chemotherapy drugs by chemical reactions with their susceptible 
reactive groups. This may cause reduction in activity, if the altered functional groups are 
important for the therapeutic activity. This causes a lack of significant therapy at the 
prescribed dosages and hence, a subsequent increase in drug administration [30].  
1.5.5. Poor solubility and stability 
Drugs used in cancer treatment are divided into two types based on their solubilities as 
hydrophilic and hydrophobic. While hydrophilic drugs are immediately assimilated in the 
blood stream if the drug administration route is intravenous, hydrophobic drugs are not 
easily soluble and hence require greater therapeutic concentrations to be as effective. 
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Also, certain drugs rapidly deteriorate under certain pH environs[31]. This is a major 
challenge as the human body contains many pH conditions for example the physiological 
pH of blood is 7.4 while that of a cancer environment is more acidic at around pH 5. This 
creates problems in delivering drugs at specific sites.   
Nanoparticles have been used as vectors to help protect and deliver anti-cancer drugs by 
attempting to circumvent these problems. They are described in greater detail in the 
following section.     
1.6. Nanoparticles used for chemotherapy 
Nanoparticles employed in chemotherapy are typically materials in the size range of 1-
1000 nm, capable of delivering therapeutics in or around the tumour 
microenvironment[32]. The small size of nanoparticles allows them to accumulate in 
tumour tissues due to the increased permeability and confinement of tumour tissue as  a 
result of the enhanced permeability and retention (EPR) effect. A size between 10-200 
nm is the most preferable size range for anti-cancer drug delivery as particles smaller than 
6 nm can be excreted by the kidney, and those larger than 300 nm can be rapidly 
recognized and removed by the reticulo-endothelial system (RES)[33]. Therefore, 
nanoparticles with this size range are circulated more in the blood after intravenous 
administration which provides more opportunity to accumulate in tumour tissues. Over 
the years, different types of nanoparticles have been constructed with the view to develop 
a fool-proof system for cancer treatment (Refer Fig 1.1.)[34]. Herein, the types of 
nanoparticle that have been used for cancer therapy have been discussed. 
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Fig 1.1: Different types of nanoparticles used in chemotherapy (Reproduced with permission from 
Masserini et al. 2013) 
1.6.1. Polymeric nanoparticles 
Polymeric nanoparticles are composed of polymer and co-polymer matrices in the form 
of nanospheres and nanovesicles[35]. Nanospheres are matrix systems, wherein the 
nanoparticle core is solid and drug molecules may be adsorbed at the sphere surface or 
encapsulated within the particle. Nanocapsules are vesicular systems where the entrapped 
substances are confined to a cavity consisting of a liquid core (either oil or water) 
surrounded by a solid material shell[36]. Commonly used polymeric materials are 
poly(lactic-co-glycolic acid) (PLGA), polylactide (PLA), polyethylene glycol (PEG), 
polyglutamic acid (PGA), polyethyleneimine (PEI), polyacrylic acid (PA), etc. 
1.6.2. Lipid based nanocarriers 
Commonly used lipid based nanoparticles include liposomes, nanostructured lipid 
carriers and solid lipid nanoparticles. These nanoparticles are favoured more for in-vivo 
applications as the lipid matrix is predominantly constructed using physiological lipids 
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which are endogenous to, and hence can be easily degraded within, the cellular milieu 
after drug delivery[37]. Commonly used lipid matrix constituents include triglycerides, 
fatty acids and phospholipids such as phosphodylcholine and phosphoethanolamine. 
1.6.3. Inorganic nanoparticles 
Inorganic nanoparticles have demonstrated commendable success in in-vivo and in-vitro 
cancer therapies and imaging due to their unique optical-electronic properties. Quantum 
dots, carbon nanotubes, gold nanoparticles (spheres, shells, rods and cages), iron oxide 
magnetic nanoparticles and ceramic nanoparticles have been employed in tumour 
targeting, imaging, photothermal therapy and drug delivery applications[38]. While they 
do suffer from several drawbacks such as non-biodegradability and non-biocompatibility, 
considerable advances have been made to address their cytotoxicity and give them stealth-
like properties[39]. 
1.6.4. Carbohydrate-based nanoparticles 
Carbohydrate-based nanoparticles have received considerable interest as drug carriers 
due to their natural origin and inherent biodegradability and biocompatibility[40]. 
Commonly used carbohydrates include cyclodextrins, chitosan, amylose, hyaluronic acid 
and heparin[41].  
1.6.5. Protein-based nanoparticles 
Protein-based nanoparticles also display biocompatibility and biodegradability[42]. 
However, these nanoparticles may show immunogenicity. Abraxane, a human serum 
albumin based nanoparticle formulation, has been successfully introduced in the market. 
Other proteins explored for nanoparticle synthesis include gelatin, legumin and gliadin.     
1.6.6. Dendrimers 
Dendrimers are synthetic organic compounds with spherical 3D structural morphology 
showing a branched structure. Features like nanoscopic size, narrow polydispersity index, 
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control over molecular structure, the presence of interior cavities and high surface 
functionalities makes them attractive candidates for delivery in biological 
applications[43]. Commonly used matrix polymers include polypropylene imine, 
polyethyleneimine and polyamidoamine (PAMAM). However, they do suffer from 
inherent toxicity due to the synthetic nature of the matrix which also makes them more 
susceptible to expulsion by the reticulo-endothelial system[44].  
1.7. Mechanisms for targeting 
Nanoparticle-mediated chemotherapy relies on two types of delivery strategies; active 
and passive (Fig. 1.2). Passively-targeted nanoparticle assemblies contain the therapeutic 
load but do not have a targeting moiety fabricated in them. This passive targeting relies 
on the enhanced permeation and retention (EPR) effect, distinctive of tumour vasculature, 
for efficient therapy[45]. The EPR effect accounts for the increased vascular permeability 
due to interendothelial gap defects, allowing extravasation of nanoparticles up to 400 nm 
in diameter, and also poor lymphatic drainage in the tumour microenvironment aiding the 
accumulation of and further release from nanoparticles[46,47].      
Passively targeted nanocarriers first reached clinical trials in the mid-1980s, wherein few 
liposomes and polymer–protein conjugates based products were marketed in the mid-
1990s[35]. Passive targeting however holds several limitations as the non-specific nature 
of the process does not warrant a complete payload delivery at the side of the tumour. 
Also certain drugs do not diffuse efficiently inside the tumours and furthermore certain 
tumours do not exhibit the EPR effect which makes unmitigated therapy improbable[48]. 
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Fig 1.2: Different mechanisms of targeting: Passive tissue targeting achieved by the increased 
permeation and retention in tumours. Active cellular targeting (inset) can be achieved by 
functionalizing the surface of nanoparticles with ligands that promote cell-specific recognition and 
binding. (Reproduced with permission from Peer et al. 2007) 
 
To overcome this limitation, specific molecules can be attached on the surface of the 
nanocarrier which are specific to a receptor or protein overexpressed on tumour cells and 
can therefore serve as markers for effective ligand binding. These surface modified 
nanoparticles will get internalized into the target cells through ligand–receptor 
interactions. Targeting ligands such as proteins (antibodies and antibody fragments), 
peptides, vitamins, carbohydrates and nucleic acids (aptamers) have been widely explored 
for this purpose[49].  
However, targeted delivery does have limitations such as the receptor capacity, tumour 
volume, cancer cell heterogeneity and differences in overexpression of cancer 
markers[50]. 
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The density of the surface target receptors plays an important role in determining doses 
and dosage regimens. If the density of the targeting receptor is less, any excess targeting 
nanocarriers will not have available binding surfaces and thus will be removed[45].  
If the targeting agent has a very high affinity for the receptor they can get trapped within 
and extravasate in the part of the tumour surrounding the capillaries, and consequently 
they do not diffuse throughout the tumour, especially in the case of large solid tumours, 
hence recurrence of cancer is more likely, even after sufficient therapeutic dosage 
administration[51]. 
The expression of a particular receptor itself may vary within the same tumour owing to 
the high frequency of mutations which are characteristic of cancer cell divisions[52].  
Therapies which rely on targeting overexpressed receptors in cancer do not consider the 
fact that although these receptors are overexpressed in cancer cells as compared to non-
cancerous cells, the number of non-cancerous cells in the body is far more than the 
number of tumorous cells and thus targeting could be considered futile.  
With the advantages and disadvantages of the targeting approaches in mind, the work in 
this thesis explored both approaches, the rationale for which is explained in the following 
section.  
1.8. Rationale  
Many of the chemotherapy drugs used today target the cellular processes such as 
increased cell multiplication which are proven cancer markers as cancerous cells require 
a greater amount of energy to account for the increased cell division, metastasis and 
angiogenesis[52]. Although these processes are amplified in cancer cells, they are not 
exclusive to them alone. Hence, normal cells undergoing mitosis and cell division can 
also be affected leading to simultaneous non-specific toxicity and cell death at areas not 
intended for action by the drugs[25]. This can in turn lead to several undesirable effects 
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such as hair loss, suppression of bone marrow, multi-drug resistance, neurological 
dysfunction and cardiac toxicity[53]. 
Phytochemicals with potent anti-cancer activity have been used as the drugs of choice in 
this thesis. The potential advantage of using phytochemicals is that they have shown 
considerable specificity for cancer cells, have a better tolerance within a living system as 
they are components of a regular diet and hence will not be harmful in case of non-specific 
delivery[54].  
Epigallocatechin gallate (EGCG) has shown potent chemopreventive and 
chemotherapeutic activity in many cancer cell lines the mechanisms of activity also being 
diverse[55–57]. Piperine, one of the most pharmacologically active components of black 
pepper, has also shown anti-cancer, anti-inflammatory and anti-oxidant activity[58,59]. 
Mangiferin from Mangifera indica has also shown a wide range of therapeutic properties 
as an anti-diabetic, anti-obesity and anti-cancer agent[60–62]. 
Two kinds of nanovehicles have been used in this study; solid lipid nanoparticles which 
have a matrix made of physiological lipids that are non-toxic. Solid lipid nanoparticles 
have a number of advantages including an improvement in drug stability and drug 
entrapment, biocompatibility and efficient scale up[63].  Chitosan nanoparticles can also 
be easily broken down within the mammalian cell, and thus do not show the accumulation 
induced toxicity associated with many other conventional nanoparticle systems such as 
the ones with inorganic metals as matrix[64]. 
Ligands have been employed in two of the projects to confer additional specificity to the 
delivery vehicles. One of these ligands is bombesin, which is a tetradecapeptide that is a 
natural homolog to the gastrin-releasing peptide receptor which is commonly 
overexpressed in many types of cancers such as breast, prostate, ovarian, lung and liver 
cancers, and it is therefore an excellent cancer biomarker[65]. The second ligand, 
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mannose, was investigated as a ligand for targeting in cancer as it is a natural homolog to 
lectin receptors which are commonly overexpressed in breast, liver, prostate and brain 
cancers[66]. A further advantage of ligand conjugation is that it can reduce the toxicity 
associated with nanoparticle delivery as the cytotoxic drug will only be delivered to the 
cells where it is aimed at and not non-tumorous cells[67].  
Prior to investigating their anti-cancer properties, the physico-chemical natures of the 
nanoparticle systems were well characterised in order to ensure their suitability for 
delivery within living systems. The mean particle size of the nanoparticles was 
characterised using dynamic light scattering technique (DLS). To study effective 
encapsulation and conjugation differential scanning calorimetry (DSC) and Fourier 
transform infrared analysis (FTIR) were used. The in-vitro anti-cancer activity was 
checked by assays in cancer cell lines. Uptake and migration assays were carried out to 
check the efficiency of the nanoparticle system to be taken up by the cells and suppress 
proliferation, respectively. 
Thus, different combinations of delivery vehicles (lipid and carbohydrate based), 
different approaches for delivery (active and passive) and different targeting ligands 
(protein and carbohydrate-based) have been explored in this work. 
1.9. Nanoparticles used in this work 
1.9.1. Solid lipid nanoparticles (SLNs) 
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Fig 1.3: Structure of an SLN (Reproduced with permission from Khatak et al. 2004.) 
 
Solid lipid nanoparticles (SLNs) are submicron sized colloidal nanocarriers prepared 
from physiological lipids which are solid at room temperature[68]. These nanoparticles 
have shown an improvement in drug stability and drug entrapment, are biocompatible (as 
they are composed of easily biodegradable lipids) and can be efficiently scaled up for 
production[69]. The most important advantage of SLNs is that they aid in the controlled, 
gradual release of the drug, thus improving the retention time and effectiveness of the 
drug while preventing premature degradation[70,71]. 
SLNs can be prepared as a variety of emulsions. The oil-in-water emulsion (O/W) is 
effective to encapsulate hydrophobic drugs that can be dissolved in the inner oil phase 
while the water-in-oil emulsion (W/O) emulsion can be used to encapsulate hydrophilic 
drugs in the inner aqueous core. In addition, a water-in-oil-in-water (W/O/W) double 
emulsion can be used to encapsulate drugs which are sensitive to pH changes. The many 
methods for preparation of SLNs are enlisted below: 
1.9.1.1.  Homogenization 
This method of preparation involves the dispersion of the organic phase with the aqueous 
phase by the use of  strong cavitation forces provided by homogenizers to help in 
formation of submicron sized nanoparticles[72]. Homogenisation is of two types: 
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1.9.1.1.1.  Hot homogenization 
Hot homogenization involves the heating of both the aqueous and organic phases to the 
same temperature followed by homogenisation to form a stable emulsion[73]. The 
temperature used is higher than the melting point of the lipids used, hence the organic 
phase exists as a lipid melt. Also, the higher temperature helps in the formation of smaller 
droplets and hence smaller nanoparticle sizes[74].  
This method is useful for heat resistant drugs which are not affected by the increase in 
temperature during heating. However, care must be taken as the temperature can increase 
during homogenisation due to the mechanical stress caused by the cavitation. Hence this 
method is not suitable for thermo-labile drugs or those susceptible to structural damage. 
1.9.1.1.2.  Cold homogenization 
This method is employed for encapsulating temperature or shear sensitive drugs where 
hot homogenization cannot be used for preparation. The drug is initially dissolved in the 
lipid melt to form a uniform organic phase. The melt is then rapidly cooled using liquid 
nitrogen to form a solid lipid. Then solid lipid is milled with a mortar to form 
microparticles, which are dispersed in an aqueous surfactant solution then into the 
aqueous phase followed by homogenization. This method typically gives larger particles 
compared to hot homogenization, however the extent of milling of the solid lipid greatly 
affects the size of the final nanoparticles. 
1.9.1.2.  Solvent evaporation and emulsification 
In this method, the lipids are initially dissolved in a water-immiscible solvent to form a 
continuous organic phase[75]. This organic phase is then homogenized into an aqueous 
phase containing surfactants to form a stable emulsion. The formed emulsion is now 
subjected to solvent evaporation by stirring, wherein the solvent is removed and the lipids 
gradually precipitate into the aqueous phase as nanoparticles. However, if the 
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nanoparticles are to be used for biomedical purposes care must be taken while choosing 
the solvents, as there could be additional toxicity induced by the use of toxic solvents[76]. 
1.9.1.3.  Microemulsion 
Microemulsions are formed by mixing a hot homogenous lipid phase into a greater 
volume of cold aqueous phase[77]. A few factors such as the velocity of addition and the 
lipophilicity of the solvents used must be considered for determining particle size. The 
faster the distribution in aqueous phase, better the polydispersity of the nanoparticle 
suspension. Also, more lipophilic solvents yield bigger particle sizes[78]. This could 
again be correlated to the easier distribution in the aqueous phase.    
1.9.1.4.  Solvent emulsification diffusion technique 
This method makes use of a solvent partially miscible with water. Initially, both the water 
and the solvent are mixed till the system reaches saturation and are in thermodynamic 
equilibrium with each other[79]. Following this, the drugs and the lipids are dissolved in 
the water saturated solvent phase. The dissolution is carried out at a higher temperature if 
the lipids used have a higher melting temperature. The surfactant phase is made by 
saturating the surfactant containing aqueous phase with the solvent. The lipid phase is 
now emulsified into the surfactant containing aqueous phase to form a primary emulsion. 
After this, more water is added to the system to allow the solvent to diffuse into the 
continuous phase and thereby causing the lipid to precipitate in a nanoparticulate form. 
The diffused solvent is now eliminated through distillation. 
1.9.1.5.  Hot melt technique 
This method involves melting of the solid lipids to form a hot lipid melt. The drug is 
dissolved in lipid melt by vigorous mixing and then emulsified in an aqueous phase that 
is heated above the melting temperature of the lipids[80]. The dispersion is then cooled 
down to produce nanoparticles. 
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1.9.1.6.  Ultrasonication 
In this method, the lipid phase is initially melted and the drug is dissolved in this hot 
phase[81]. The aqueous phase is then heated to the same temperature and added to the 
lipid phase dropwise with ultrasonication. Dispersion occurs due to the strong cavitation 
forces supplied by the ultrasonicator. This method does not involve the use of organic 
solvents and hence, is preferred for nanoparticle applications due to its minimal toxicity. 
1.9.1.7.  Solvent injection method 
The principle of this method involves lipid precipitation from the dissolved lipid into the 
aqueous solution while the lipid is initially dissolved in a water miscible solvent[82]. The 
lipid-solvent mixture is then slowly added with an injection needle into the aqueous phase 
with or without surfactants. The mixing step is performed while the aqueous phase is 
under stirring, to maintain homogeneity and uniform particle size. 
1.9.1.8.  Supercritical fluid technique 
A fluid is called supercritical when its pressure and temperature exceed their critical 
value. Beyond the supercritical point, the ability of a fluid to dissolve substances is found 
to increase. CO2 has been routinely used as the gas for producing super critical fluid (SFC) 
in this method as it is inexpensive, non-inflammable and inert to the drugs. Initially, the 
drug is dissolved in the solvent and this drug-solvent mixture is allowed to dissolve in the 
SFC. The SFC acts as an anti-solvent, wherein it reduces the solubility of solid in the 
solution and therefore the solid precipitates as nanoparticles[83]. 
1.9.1.9.  Double emulsification method 
This is a two-step process, wherein in the first step, the drug (hydrophilic) is dissolved in 
an aqueous solvent (inner aqueous phase) and then dispersed in a lipid containing an 
emulsifier (e.g. lecithin), known as oil phase, to produce a primary emulsion (w/o). A 
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double emulsion (w/o/w) is formed after addition of aqueous solution of the hydrophilic 
emulsifier (e.g. Poloxamer, PVA) followed by stirring to evaporate organic solvent[84].  
Double emulsification avoids the use of high temperatures to melt the lipid for the 
preparation of protein and drug-loaded lipid nanoparticles and there is a scope for surface 
modification of the nanoparticles to provide steric stability by using a lipid-PEG 
derivative. Steric stabilization significantly improves the stability of these colloidal 
systems against pH and electrolyte concentration changes in the gastrointestinal fluids. 
1.9.2.  Chitosan nanoparticles 
 
 
Fig 1.4: Structure of chitosan polymer (Reproduced with permission from the Chemistry Glossary) 
 
Chitosan (CS) is a linear copolymer of β-(1–4)-linked D-glucosamine and N-acetyl-D-
glucosamine whose molecular structure comprises a linear backbone linked through 
glycosidic bonds[85]. The deacetylated chitosan backbone of glucosamine units has a 
high density of basic amine groups which are protonated and thus positively charged in 
most physiological fluids[86].  
CS is considered hydrophilic, but the percentage of acetylated monomers and their 
distribution in the chains has a critical effect on its solubility and conformation in aqueous 
media. Because of these molecular features, CS exhibits a pH-dependent behaviour and 
interesting biopharmaceutical properties such as muco-adhesiveness and the ability to 
open epithelial tight junctions[87]. 
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The presence of amino (-NH2) and hydroxyl (-OH) groups in chitosan provides 
opportunity for a high degree of chemical modification. Chitosan is an interesting 
polymer to prepare nanoparticles, as it is biocompatible, nontoxic, biodegradable and has 
shown absorption-enhancing effects[87]. Due to the availability of free amino groups, it 
carries a positive charge under physiological conditions and reacts with many negatively 
charged surfaces such as the cell membrane. CS is insoluble in water and organic solvents, 
however, it is soluble in dilute aqueous acidic solution (pH<6.5), which can convert the 
glucosamine units into a soluble form of protonated amine (R–NH3+)[88]. CS is also 
known to precipitate in alkaline solutions or with polyanions and form a gel at a lower 
pH[89]. 
 
Fig 1.5: Preparation of chitosan nanoparticles (Reproduced with permission from Mukhopadhyaya 
et al.)  
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Chitosan nanoparticles can be prepared by many methods such as the following: 
I. Ionotropic gelation 
Ionic cross linking is based on electrostatic interaction to form chitosan nanoparticles 
using a negatively charged cross linker such as a triphosphate which can make ionic bonds 
with positively charged chitosan molecules, thus forming cross linked polymers. This 
method has been widely used to encapsulate proteins and drugs as it avoids the use of 
strenuous temperature conditions and organic solvents[90]. 
II. Covalent conjugation: 
Covalent cross linking involves formation of covalent bonds between chitosan chains and 
cross linking agents such as glutaraldehydes and polyethylene glycol which helps in the 
covalent linking of the chitosan chains[85]. Nanoparticles with a narrow size distribution 
have been produced by this method. 
III. Precipitation 
Precipitation is carried out in two ways. In desolvation, a flocculating agent is added to 
an aqueous chitosan solution. The decrease in solubility due to the addition of the 
flocculant causes chitosan to precipitate out by the formation of hydrogen bonds. Solvent 
emulsification involves the addition of an organic phase containing a drug into the 
aqueous chitosan solution. Emulsifiers may be added to reduce the surface tension 
between both phases. The interaction of the two phases creates turbulence which results 
in  of precipitation of chitosan nanoparticles[91]. 
IV. Radical polymerization 
Radical polymerization involves the use of acids and strong conditions such as high 
temperatures[92]. Chitosan is dissolved in dilute nitric acid solution and then stirred with 
ceric ammonium nitrate, nitric acid and isobutyl cyanoacrylate at 40 °C for 40 minutes in 
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an inert nitrogen environment. This method can be fine-tuned for core and shell properties 
by using different monomers.    
V. Complex formation 
Due to the positive charge on the chitosan chain, it can be used to form ionic complexes 
with anionic drugs[93]. Ionic complexes have been formed with retinol encapsulated in 
chitosan by this method with a particle size of around 102.6 ± 12.0 nm. Encapsulation of 
retinol in chitosan incidentally caused a 1,600-fold increase in its solubility.  
VI. Spray drying 
This method involves spray drying of chitosan along with another metal oxide that it can 
be chelated with. Iron oxide and chitosan nanoparticles have been prepared by this 
method[94]. It is a one-step simple method for the preparation of chitosan nanoparticles. 
VII. Polyelectrolyte formation 
This method involves charge neutralisation of the cationic polymer by use of a negatively 
charged anionic component such as a DNA molecule to form a  polyelectrolytic 
complex[95]. The preparatory method is comparatively mild and requires no 
sophisticated instrumentation. A negatively charged anionic solution can be added slowly 
to the chitosan dissolved in acetic acid under stirring and slow addition to give chitosan 
nanoparticles. 
1.10. Drugs used in this study 
1.10.1. Epigallocatechin gallate (EGCG) 
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Fig 1.6: Structure of EGCG 
IUPAC name: [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl) chroman-3-yl] 3,4,5-
trihydroxybenzoate 
Molecular weight: 458.372 g/mol 
Solubility: Water, ethanol 
Epigallocatechin gallate is one of the most abundant catechins found in green tea. It has 
shown anti-diabetic, anti-obesity and anti-cancer potential[96–99]. It has shown to 
downregulate mRNA and protein expression of MMP-2 matrix metalloproteinases, which 
play an important role in the degradation of the basement membrane, angiogenesis and 
metastasis, in MCF-7 breast cancer cell line[100]. It induces prostate cancer cell death by 
suppressing androgen receptor acetylation in androgen dependent prostate cancer cell line 
LNCaP [101]. EGCG has also shown microRNA targeting potential by upregulating miR-
210 microRNA leading to reduced proliferation and anchorage-independent growth in 
H1299 and H460 lung cancer cells[102]. It induces apoptosis in HT-29 colon cancer cells 
by upregulation of caspase-3 activity and mitochondrial damage [103]. The structure 
consists of three aromatic rings with eight free hydroxyl groups (Fig 1.6). Much of the 
beneficial activities of EGCG are linked to its structure. However, the free hydroxyl 
groups are susceptible to easy reactions within the biological system by enzymes leading 
to an overall loss in activity.   
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1.10.2. Piperine 
 
 
                                                          Fig 1.7: Structure of piperine 
 
IUPAC name: (2E,4E)-5-(1,3-Benzodioxol-5-yl)-1-(1-piperidinyl)-2,4-pentadien-1-on 
Molecular weight: 285.338 g/mol  
Solubility: Chloroform, ether, acetic acid 
Piperine accounts for 5-9% by weight of the components in black pepper. It has been 
known as a prominent anti-oxidant, anti-inflammatory and more recently an anti-cancer 
agent[104,105].The anti-cancer effect of piperine may be attributed to the inhibition of 
NF-κB, c-Fos, ATF-2 and CREB activities, suppression of angiogenesis by inhibiting Akt 
phosphorylation, or blockade of the production of pro-inflammatory cytokines and the 
activity of matrix metalloproteinases that are likely to promote tumour growth and 
metastasis[104]. 
1.10.3. Mangiferin 
 
Fig 1.8: Structure of mangiferin 
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IUPAC Name: (1S)-1,5-Anhydro-1-(1,3,6,7-tetrahydroxy-9-oxo-9H-xanthen-2-yl)-D-
glucitol 
Molecular weight: 422.34 g/mol 
Solubility: ethanol, DMSO  
Mangiferin, obtained from the bark, leaves and pulp of Mangifera indica, is a polyphenol 
used in ancient Indian Ayurvedic and Chinese medicine. The structure consists of a C-
glycosidic derivative attached to a xanthenone. It has shown anti-oxidant, anti-diabetic, 
anti-allergic, anti-HIV and anti-cancer activities[60]. 
Mangiferin exhibits its anti-cancer activity by downregulating inflammation, arresting 
cell cycle, reducing proliferation/metastasis, promoting apoptosis in malignant cells and 
also providing protection against oxidative stress and DNA damage[106]. A study has 
shown that mangiferin reduced the tumour volumes similar to that of conventional 
anticancer drugs such as Cisplatin[107]. However, the drug shows low bioavailability 
which can be addressed by the use of appropriate delivery vehicles[60]. 
1.11. Ligands used in the study 
1.11.1. Bombesin 
Bombesin receptors are a type of G-protein coupled receptors and have 4 subtypes- BB1, 
BB2, BB3 and BB4. BB1 is known as the neuromedin B (NMB) receptor because of its 
affinity towards mammalian ligand NMB. The BB2 receptor with high affinity to 
mammalian gastrin releasing peptide (GRP) is called the GRP receptor[65].  
Reubi et al. investigated 161 cancer cell lines, out of which 12 prostate cancer cell lines, 
41 breast cancer cell lines, 5 gastrinomas and 3 of 9 small cell lung carcinomas expressed 
predominantly GRP receptors; 11 of 24 intestinal, 1 of 26 bronchial, and 1 of 1 thymic 
carcinoids had preferentially NMB receptors whereas 9 of 26 bronchial carcinoids, 1 large 
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cell neuroendocrine lung carcinoma, and 4 of 9 small cell lung carcinomas had 
preferentially BB3 receptors[108]. 
 
Fig 1.9: Structure of Bombesin receptor BB2 (Reproduced with permissions from Atlas of Genetics 
and Cytogenetics in Oncology and Haematology) 
 
GRPR is a transmembrane glycoprotein with 7 transmembrane domains consisting of 384 
amino acids. Bombesin is a tetradecapeptide originally isolated from the toad Bombina 
bombina. GRPR has shown to bind bombesin with very high affinity, internalising via 
receptor-mediated endocytosis[109].   
 
Fig 1.10: Structure of bombesin 
1.11.2. Mannose 
C-type lectins are a group of carbohydrate-binding membrane proteins, commonly 
functioning as components in cell adhesion, glycoprotein turnover, pathogen recognition 
and apoptosis[12]. Most of them contain an extracellular carbohydrate recognition 
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domain (CRD) that helps in the detection of free carbohydrates or in complexed forms 
like glycoproteins or glycolipids. Internalization of carbohydrates takes place through 
clathrin-mediated endocytosis. C-type lectins are commonly overexpressed in a variety 
of cancers such as liver, lung and ovarian cancers. Mannose is an aldohexose sugar (an 
epimer of glucose), which is a common ligand to C-type lectin receptors. Hence, mannose 
was used as the ligand for lectin targeting. Glyco-targeting is gaining importance as these 
targeting ligands are not foreign to the cellular system and have negligible toxicity, thus 
preventing expulsion by the RES system[66].  
 
 
Fig 1.11: Structure of D-mannose (Reproduced with permission from the Medical Biochemistry) 
1.12. Techniques used in the study 
A. Dynamic light scattering  
Dynamic light scattering technique can help measure particle size as small as 1 nm in 
diameter. The sample is illuminated with a laser beam. The scattered light is detected by 
a photon detector. Analysis of the fluctuation of the scattered light provides the diffusion 
coefficient D which can be used to calculate radius of the particle R by the Stokes-Einstein 
Equation: 
𝐷 =
𝑘𝐵T
6πηR
 
Where kB is the Boltzmann-constant, T is the temperature and η is the viscosity.  
The zeta potential indicates the surface charge on a particle, and therefore provides 
information about the electrostatic repulsion with adjacent particles and thus its stability. 
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Theoretically, it is the electric potential at the slipping planes between the Stern layer 
surrounding the particle and the diffused layer in contact with the dispersion 
medium[110]. Thus, the greater the surface charge, the higher the repulsion with similar 
particles, and hence the greater its resistance towards aggregation.  
In addition to measuring the particle size DLS provides information about the 
polydispersity of the sample. Polydispersity measures the heterogeneity or non-
uniformity of a sample between index values of 0 and 1. The more heterogeneous a 
sample is, the greater will be the value of the polydispersity index.  
B. Fourier transform infrared (FTIR) analysis  
FTIR technique helps in obtaining different vibrational frequencies of molecular 
interactions within a sample. When a sample is irradiated with infra-red radiation, 
absorbed IR radiation excites molecules into a higher vibrational state. Bonds between 
different heteroatoms give rise to distinct vibrational frequencies to give an infrared 
spectrum which can be used to determine the nature of chemical interactions between 
drug molecules, excipients and matrix of nanoparticles. A detector measures the intensity 
of transmitted or absorbed light as a function of its wavelength.   
The FTIR spectra are represented as plots of intensity versus wavenumber (which is the 
reciprocal of the wavelength and is given in units of cm-1), with the intensity plotted as 
the percentage of light transmittance or absorbance at each wavenumber. 
C. Differential scanning calorimetry (DSC)  
DSC is a thermo-analytical technique which evaluates heat changes during phase 
transitions and chemical reactions as a function of temperature. In this technique, the 
sample and reference are heated to the same temperature in hermetically sealed pans in 
an inert environment. The DSC thermogram is a curve of heat flux versus temperature or 
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time. This curve can be used to calculate enthalpies of transitions obtained by integrating 
the peak corresponding to a given transition using the given equation: 
ΔH = KA 
where ΔH is the enthalpy of transition, K is the calorimetric constant, and A is the area 
under the curve. 
During phase transitions, energy is either absorbed or released. If it is an endothermic 
process such as protein denaturation and reduction reactions more heat must be supplied 
to the sample for it to remain at the same temperature as the reference. Therefore, the 
enthalpy will be positive. In an exothermic reaction, such as crystallization, less heat 
needs to be provided to the sample hence the enthalpy change of that of the sample relative 
to the reference is negative. DSC was used in the study for the determination of the phase 
transition of the drugs post encapsulation inside the nanoparticles. 
1.13. Aims and objectives 
Aims of this research work: 
The main aim of this thesis work was to develop and evaluate various nanoformulations 
for the delivery of phytochemicals to enhance their stability and cytotoxicity. 
Major Objectives: 
➢ To develop different nanocarriers and nano-carrier combinations for 
delivery of phytochemicals as anti-cancer drugs. 
➢ To improve therapeutic efficacy of phytochemicals by providing a stable 
nanocarrier system for delivery 
These research aims were achieved by the use of the following methodogies: 
➢ To optimize formulation and process variables for the development of 
biocompatible nanoparticles. 
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➢ To characterize nanoformulations using different analytical techniques such 
as UV-Visible spectroscopy, dynamic light scattering, Fourier transform infrared 
and differential scanning calorimetry techniques. 
➢ Bioconjugation of a targeting ligand on the surface of drug loaded 
nanoparticles to prepare targeted nanoparticles. 
➢ To study the release patterns of encapsulated phytochemicals from 
nanoparticle systems. 
➢ Evaluation of in vitro cytotoxicity of targeted and non-targeted, drug-
encapsulated nanoparticles in comparison to pure drug. 
➢ To study the cellular uptake of nanoparticles by using fluorescent dye-
loaded nanoparticles. 
➢ To study the in-vivo efficacy of targeted formulations by using suitable 
animal model 
➢ To study the in-vivo efficacy of targeted formulations by survival studies 
and changes in tumour volume and body weight.  
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2.1. Background 
Tea, obtained from the cured leaves of the tea shrub Camellia sinensis, has been known 
as a health promoting beverage since ancient times; its medicinal properties discovered 
as early as the 5th century AD[1]. Most of the health benefits associated with drinking 
tea including its anti-obesity and anti-oxidant effects  have been attributed to its 
polyphenolic constituents, especially its catechins including epigallocatechin gallate 
(EGCG), (-)-epigallocatechin, (-)-epicatechin gallate and (-)- epicatechin [2–4]. EGCG is 
one of the most abundant and active constituents of green tea with extensive therapeutic 
properties[5,6]. Research on EGCG has shown that it exhibits a wide array of therapeutic 
potencies including anti-inflammatory, anti-diabetic, anti-obesity and anti-cancer 
effects[5,7–10]. EGCG has been found effective not only as a chemopreventive but also 
as a potent chemotherapeutic agent[11–13]. It has been documented to possess anti-
cancer activity in many cancer cell lines by inhibiting tumorigenesis, proliferation and 
angiogenesis[14–16]. Many pathways have been elucidated to explain the anti-cancer 
activity of EGCG as described below: 
a. Telomerase activity inhibition 
Telomeres are long repeating, highly-conserved, end-nucleotide sequences in eukaryotic 
cells that help cells to divide without losing any of the crucial genes in the process[17]. 
During cell replication, the enzyme DNA polymerase uses each strand of the DNA as a 
template to synthesize two daughter strands[18]. 
However, the enzyme is not able to completely replicate the entire strand, and hence there 
is a shortening of the end of the strand following each division. Telomeres help in 
preserving the important genetic sequences by getting shortened themselves in the 
process[17]. Telomerase is an RNA-dependent DNA polymerase (reverse transcriptase) 
that helps replenish the units of the telomeres. In most somatic cells, there is no telomerase 
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so the cells cease replicating following a certain number of divisions[19]. Expression of 
telomerases is upregulated in a number of cancers thus leading to the maintenance and 
the continuous replication of genetic material[20]. EGCG has shown to inhibit telomerase 
activity in a number of cancers, thus leading to cell division cessation[21]. 
b. Gene silencing 
DNA hypermethylation is the process of the addition of methyl groups to the DNA strand 
by the enzyme DNA methyltransferase. When the DNA subunits at the promoter region 
of a gene are hypermethylated, there is no binding of the transcription factors at this 
portion leading to gene silencing[22]. Cancer cells are found to induce hypermethylation 
at the regions of the DNA that contain pro-apoptotic genes in order to maintain continuous 
cell multiplication[23]. EGCG is found to directly inhibit DNA methyltransferase and 
also causes reactivation of methylation-silenced genes leading to increased apoptosis 
among cancer cell populations [24]. 
c. Angiogenesis 
Angiogenesis is a process of neovascularization wherein new blood vessels are formed 
from existing ones. Cancer cells upregulate angiogenesis in order to compensate for the 
greater blood supply and nutrients required for the highly escalated rate of cell 
division[25]. The process includes disruption of the basement membrane to allow 
migration of angiogenic factors which help recruit new vessels. Vascular endothelial 
growth factor (VEGF) is one such potent angiogenic factor upregulated in angiogenesis 
[26]. 
EGCG has been reported to inhibit VEGF expression by downregulating expression of 
hypoxia-inducible factor-1α which is a VEGF stimulator. Also, the hypoxia and oxidative 
stress in cancer cells leads to production of oxygen radicals, which activate transcription 
factors such as nuclear factor kappa-B(NFκB), that also cause overexpression of VEGF. 
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EGCG is also found to downregulate expression of NFκB, thus indirectly reducing 
VEGF[27]. 
d. Metastasis 
Metastasis is the movement of cancer cells from the primary area of tumour development 
to other parts of the body through blood vessels or the lymphatic system. It involves the 
degradation of the basement membrane which causes disruption of the membrane wall, 
helping dissemination of cancer cells to cause tumour formations elsewhere[28]. EGCG 
has been found to inhibit matrix metalloproteinases 2, 3 and 9 which are important in the 
degradation of the basement membrane, thus preventing the spread of tumour to other 
areas[29]. 
e. Apoptosis 
Apoptosis is a process of programmed cell death that occurs through two pathways- 
intrinsic and extrinsic. The extrinsic pathway functions by the activation of death 
receptors by binding which triggers a cascade to allow the release of caspases that bring 
out events in apoptosis. The intrinsic pathway involves pro-apoptotic proteins such as 
BCL-2-associated X protein (BAX) and BCL-2 homologous antagonist killer (BAK) that 
triggers activation of caspases. This pathway is regulated by anti-apoptotic proteins such 
as B-cell lymphoma 2 (BCL-2) and B cell lymphoma extra-large (BCL-XL), which 
antagonize with BAX and BAK. Cancer cells have shown to supress apoptotic pathways 
to maintain immortality[30]. EGCG has been shown to promote the expression of pro-
apoptotic proteins BAX and BAK while also consequently inhibiting the expression of 
BCL-2 and BCL-XL in many cancer types[31,32]. 
f. Anti-proliferative activity 
Mitogen activated protein kinases (MAPK) are enzymes involved in important steps for 
cell survival, proliferation and development of cancer cells[33]. EGCG has shown to 
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inhibit MAPK pathway in many cancer cell types. It has also been shown to inhibit 
insulin-like growth factor-I receptor activity which helps to activate the MAPK pathway 
and plays an important role in proliferation[34]. 
 
Fig 2.1: Structure of epigallocatechin gallate 
EGCG’s diverse therapeutic properties are attributed to its polyphenolic structure that 
allows electron delocalization on the benzene ring helping quench free radicals[35]. It has 
a trihydroxy group substitution on one ring and an esterified gallate group attached to 
another. However, it has been found to be unstable in neutral and alkaline conditions; 
undergoing rapid degradation involving the deprotonation of the hydroxyl groups[36]. 
Also, the hydroxyl groups are susceptible to various biotransformation reactions within 
the living system such as glucuronidation, methylation and sulphonidation leading to a 
loss in biological activity[37]. This instability has also been cited as one of the reasons 
for the poor bioavailability of EGCG and other catechins within the biological 
system[38]. In this study, the stability of EGCG in solutions of different pH was initially 
investigated to determine the pH range where EGCG is stable at room temperature. Then, 
EGCG was encapsulated in solid lipid nanoparticles (SLNs) for enhancing the stability 
and anti-cancer activity of EGCG. SLN were prepared from biocompatible lipids which 
are solid at room and body temperature[39]. They provide multiple advantages over other 
conventional nanocarriers such as lipid nanoemulsions and polymeric nanoparticles. 
These advantages include an improvement in drug stability, drug entrapment and 
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biocompatibility, as they are composed of easily biodegradable excipients, and offers 
efficient scaling up for production[40,41]. Moreover, SLN control the release of a pH-
sensitive drug such as EGCG and therefore, prevent the premature degradation of 
encapsulated drug in the biological system[42,43]. Post encapsulation of EGCG in SLN, 
the anti-cancer activity of pure EGCG and EGCG-loaded SLN (EGCG-SLN) was 
checked by cellular proliferation assays in MDA-MB-231 human breast cancer and DU-
145 human prostate cancer cell lines. 
2.2. Materials 
Glycerol mono-stearate (GMS) was purchased from Alfa Aesar (Johnson Matthey 
Chemicals, Hyderabad, India). EGCG, tristearin (TS), tripalmitin (TP), stearic acid (SA), 
Pluronic F68 (P F68), polyvinyl alcohol (PVA), Roswell Park Memorial Institute 
(RPMI)-1640 medium, fetal bovine serum (FBS), trypsin–EDTA, phosphate buffered 
saline (Ca2+, Mg2+ free), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), dimethyl sulfoxide (DMSO) were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Soya lecithin was purchased from HiMedia (Mumbai, India). MDA-MB-231 
human breast cancer cells and DU-145 human prostate cancer cells were obtained from 
American Type Culture Collection (ATCC, Manassas, USA). Dichloromethane was 
obtained from Merck chemicals (Mumbai, India). Tween180 was purchased from sd Fine 
Chemicals Limited (Hyderabad, India). 
2.3. Methods 
2.3.1. Aqueous Stability 
The stability of EGCG was determined in different aqueous solutions; 0.1 N HCl (pH 
1.5), phosphate buffer saline pH 7.4 (PBS), normal saline and phosphate buffer solutions 
of different pH (5, 7.4 and 9). A stock solution of EGCG was prepared (1 mg/mL) and 
dilutions were made in the study medium to give a final drug concentration of 50 µg/mL. 
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UV-Visible spectroscopy was used to evaluate changes in the absorption characteristics 
of EGCG throughout the study at λmax of EGCG at 274.5 nm. Samples were scanned in 
the range of 200-800 nm and spectra were obtained in the various solutions at different 
time points of 0, 4, 8, 24, 48 and 96 h using a Jasco-UV650 spectrophotometer.  
2.3.2. Optimization 
The most important aspect of nanoparticle preparation for biomedical applications is the 
regulation of nanoparticle sizes and particle surface charges for obtaining optimum 
dimensions as the cell endothelia and tumour microenvironments have stringent 
limitations. The synthesis of nanoparticles was optimized with respect to different process 
and formulation parameters such as the type of lipid, lipid to co-lipid ratio, surfactant used 
and its concentration, amount of co-emulsifier, inner aqueous phase volume and 
sonication time.  
2.3.3. Preparation of EGCG loaded solid lipid nanoparticles (EGCG-SLNs) 
EGCG-SLNs were prepared by emulsion-solvent evaporation method as reported in the 
literature[43].  Briefly, 80 mg GMS, 20 mg SA and 20 mg soya lecithin were dissolved 
in dichloromethane and sonicated for 3 min. EGCG was dissolved in 500 µL distilled 
water and 2 % w/v Pluronic F68 solution was then added to the lipid mixture to form a 
water-in-oil (w/o) primary emulsion. The mixture was sonicated for 5 min and then 
transferred into 1 % w/v Pluronic F68 solution to form a double emulsion. The emulsion 
was stirred for 2 h to evaporate the organic solvent. The nanoparticle suspension was 
centrifuged and washed thrice with distilled water to remove any free drug adhering to 
the nanoparticle surface. Blank nanoparticles (Blank-SLNs) were prepared in a similar 
manner, excluding the drug. 
2.3.4. Determination of drug entrapment efficiency  
The drug entrapment efficiency (EE) was calculated by the indirect method. The 
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supernatant obtained after centrifugation of the nanoparticle suspension was used for 
estimation of the free drug content by UV/Visible spectroscopy at the absorption maxima 
of EGCG at 274.5 nm. The percent entrapment efficiency was calculated by the following 
formula: 
% 𝐸𝐸 =
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝐸𝐺𝐶𝐺 𝑎𝑑𝑑𝑒𝑑 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓𝐸𝐺𝐶𝐺 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐸𝐺𝐶𝐺 𝑎𝑑𝑑𝑒𝑑
×100 
 
2.3.5. Physico-chemical characterization of nanoparticles 
2.3.5.1. Particle size and surface potential 
The mean particle diameter (PD), polydispersity index (PDI) and surface potential of 
Blank-SLN and EGCG-SLN were measured by photon correlation spectroscopy using a 
Zetasizer Nano-ZS (Malvern Instrument Ltd., Malvern, UK). Samples were diluted 
appropriately and were analysed at 25 °C with a backscattering angle of 173°. 
2.3.5.2. FTIR spectroscopy (FTIR) 
FTIR analysis of EGCG-SLN and Blank-SLNs was carried out by potassium bromide 
(KBr) pellet method, using an IR spectrophotometer (Perkin Elmer, USA). Pellets were 
prepared by adding approximately 3 mg of the sample to 100 mg of KBr. Samples were 
scanned in the range of 400–4000 cm−1.  
2.3.5.3. Differential scanning calorimetry (DSC) 
DSC analysis of EGCG-SLN and EGCG were carried out on a DSC1 instrument (Mettler 
Toledo, Switzerland). The instrument was calibrated using pure indium. Approximately 
5 mg of sample was heated in a hermetically sealed flat-bottom aluminium pan and 
scanned from 50 °C to 240 °C at a heat flow rate of 10 °C/min, under a nitrogen 
environment. Empty aluminium pans were used as standards. 
2.3.6. In-vitro drug release 
In-vitro drug release studies were performed by dialysis method in sodium acetate buffer 
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pH 5 (SAB). EGCG-SLN, equivalent to 2 mg of EGCG, was placed in dialysis tubing 
and kept in a beaker containing 100 mL of SAB and maintained at 37 °C. At 
predetermined time interval, a definite volume was withdrawn and replaced with same 
volume of fresh media. The EGCG concentration was determined by measuring the 
absorbance at 274.5 nm using a UV/Visible spectrophotometer. 
2.3.7. In-vitro cytotoxicity studies 
In-vitro cytotoxicity of native EGCG and EGCG-SLN against MDA-MB-231 human 
breast cancer cells and DU-145 human prostate cancer cells was evaluated by MTT assay. 
MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells were 
cultured in RPMI-1640 and DMEM medium, respectively, supplemented with 10% FBS, 
100 mg mL-1 streptomycin, 100 U mL-1 penicillin, and at 37 °C in a 5% CO2 incubator. 
Cells (5 × 103 cells per well) were seeded in a 96-well plate and incubated with different 
concentrations of test formulations. After 48 h, the medium was replaced with serum-free 
medium containing 0.5 mg mL-1 of MTT reagent and further incubated for 4 h. Then the 
medium was removed and formazan crystals generated by live cells were dissolved by 
adding 150 µL of DMSO in each well. The absorbance was measured using a microplate 
reader at a wavelength of 570 nm. The relative cell viability (%) was determined by 
comparing the absorbance with control wells. Data are presented as average ± SD (n = 
4). 
Cell apoptosis was detected by assessment of nuclear morphology staining with Hoechst 
33342. MDA MB-231 and DU145 cell lines were seeded in a 12-well culture plate at a 
density of 1 x 105 cells per well, cultured at 37 ºC, 5% CO2 incubator to obtain confluency. 
The cells were treated with EGCG and EGCG-SLN formulation at IC-50 concentration 
of drug-loaded formulations and incubated for 24 hrs. After incubation, the cells were 
washed with ice cold PBS for twice, fixed with 4% paraformaldehyde in PBS (pH 7.4) 
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for 15 min at room temperature, stained with 5 µg/mL Hoechst 33342 in PBS for 15 min 
and washed twice with ice cold PBS. The cells were then examined using fluorescence 
microscopy. 
2.3.8. Colloidal and serum stability studies 
2.3.8.1. Colloidal stability of nanoparticles in serum and physiological 
conditions 
Colloidal stability of EGCG-SLNs with time was tested in PBS, plasma and distilled 
water. A stock solution (1 mg/mL) of nanoparticle suspension was prepared in distilled 
water. Aliquots of the stock solution were then taken and dispersed in the respective 
medium. The samples were stored at room temperature and the particle size, 
polydispersity and zeta potential were measured at different time intervals using a 
Zetasizer Nano-ZS. 
2.3.8.2. Electrolyte-induced aggregation 
The effect of electrolytes on the solid lipid nanoparticle formulation was studied by 
electrolyte-induced aggregation technique as reported in literature[44]. Sucrose sulphate 
solutions were prepared in varying concentrations to study the behaviour of EGCG-SLNs 
in the presence of a flocculating agent.  Briefly, 16.7 g of sucrose was dissolved in 100 
mL double distilled water to give 16.7 % sucrose solution. Sodium sulphate was added to 
this native solution to make a 2 M sucrose sulphate solution. Serial dilutions were made 
from this stock solution to prepare final concentrations ranging from 0.1 to 2 M. 
Nanoparticle suspensions equivalent to 1 mg/mL were added to the serial dilutions to 
make a final volume of 3 mL and immediately analysed for particle size, zeta potential, 
polydispersity and UV-Visible absorbance. 
2.4. Results and discussion 
2.4.1. Aqueous stability 
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The stability of EGCG in solutions of different pH was evaluated with UV/Visible 
spectroscopy at 274.5 nm which is the absorption maxima for EGCG (Fig.2.2). The 
absorption characteristics for EGCG in 0.1 N HCl (pH 1.5), PBS (pH 7.4), normal saline 
(0.9 %w/v) and phosphate buffer solutions with three different pH values 5, 7 and 9 were 
recorded. This study was carried out to evaluate the behaviour of free EGCG when it is 
released in solutions simulating the different environment it encounters when released in 
the blood stream. Spectra were recorded in the wavelength range of 200-800 nm up to 96 
h to compare the changes in the drug absorption characteristics with changes in the study 
environment. EGCG was found to be most stable at highly acidic pH 1.5 in 0.1 N HCl, 
showing practically no degradation up to 96 h. In distilled water, the peak intensity for 
EGCG is found to change after 4 h but the absorption characteristics remained same till 
96 h. At 96 h, the peak is found to disintegrate, which could be due to the formation of 
degradation products. In 0.9 % w/v normal saline, the peak distorted at around 4 h, but 
complete peak disintegration occurred at 24 h. In PBS, the peak absorption showed a 
slight change after 4 h but after 24 h complete peak disintegration was observed. At pH 
5, the absorption characteristics remain unchanged up to 24 h after which distortion is 
seen at 48 h. At pH 7, peak changes were observed at 8 h but peak distortion occurred at 
24 h. EGCG was most unstable at alkaline pH 9. At this pH, changes in the absorption 
characteristics are observed immediately after addition and complete disintegration of the 
peak was observed after 4 h. These results suggested that EGCG is highly stable at acidic 
pH while its stability decreases as the pH tends towards neutral and shows very less or no 
stability at highly alkaline conditions. 
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Fig 2.2: UV/Visible spectra of EGCG (50 µg/mL) at different time points in (a) distilled 
water (b) 0.1 N HCl (c) normal saline (0.9 % w/v NaCl) (d) phosphate buffer saline pH 7.4 
(e) phosphate buffer pH 5 (f) phosphate buffer pH 7 (g) phosphate buffer pH 9 
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2.4.2. Optimization of different parameters for the blank SLN 
Blank nanoparticles without EGCG encapsulation were prepared by double 
emulsification method followed by solvent evaporation. This method shows high 
potential for encapsulation of hydrophilic drugs alike. Stearic acid served as charge 
modifier as the free carboxylic acid groups of stearic acid renders generation of 
electronegative nanoparticles which in-turn can be harnessed for other applications 
including ligand conjugation. Formulation and process parameters such as type of lipid, 
lipid to co-lipid ratio, type of surfactant and concentration, amount of co-surfactant, 
aqueous phase volume, sonication and stirring time were sequentially optimized 
2.4.3. Influence of formulation parameters  
Lipid crystallinity, lipophilicity, loading capacity, melting point and purity are important 
factors to be considered when choosing a lipid for a nanoparticle formulation[45,46].  
Tristearin (TS), tripalmitin (TP) and glycerol mono-stearate (GMS) were used for 
optimization of particle diameter and surface potential (Table 2.1). The observed particle 
size for SLN prepared with TS, TP and GMS were 131.1 ± 2 nm, 133.8 ± 2.7 nm and 
121.4 ± 2.6 nm respectively. SLN prepared with GMS not only showed the least particle 
size, but also had the least polydispersity. The co-lipid used in SLN preparation was 
stearic acid which also acted as a charge modifier. Greater surface potential correlates 
with greater stability of nanoparticles as there is a corresponding increase in the 
electrostatic repulsive forces with an increase in the charge on each particle[47]. Stearic 
acid content was varied between 30%, 20% and 10%w/w of total lipid content. Stearic 
acid at 20% w/w of lipid showed a particle diameter of 125.7 ± 2.7 nm and good surface 
potential values with least polydispersity. Surfactants stabilize the nanoparticles in the 
colloidal state and prevent agglomeration during growth and storage.  
The choice of stabilizers is important not only to control particle size and stabilization of 
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dispersions but also to control crystallization and polymorphic transitions[48]. SLN made 
with polyvinyl alcohol, Tween® 80 and Pluronic F68 showed a particle diameter of 175 
± 3.9 nm, 153.6 ± 3.4 nm and 127.5 ± 2.4 nm, respectively. SLN prepared with Pluronic 
F68 showed the smallest particle size compared to the other surfactants. The 
concentration of surfactant was varied from 1 to 3% Pluronic F68. SLN prepared with 
2% Pluronic solution showed greater uniformity with lesser particle size and hence was 
chosen as the surfactant utilized in preparation. Excess lipid molecules employed in the 
production form small, stray, unilamellar vesicles which exhibit limited mobility and 
therefore they are unable to immediately cover the newly created crystalline interfaces 
during lipid recrystallization, leading to aggregation, wherein co-emulsifiers help in 
providing additional stability during recrystallization events[49]. The co-emulsifier 
employed was soya lecithin (30% phosphatidylcholine) as it has been found to be efficient 
in the solvent-evaporation method for preparation of SLN[40]. It was optimized between 
10 and 30 mg of which 20 mg soya lecithin showed a higher surface potential with lesser 
particle diameter. The inner aqueous phase volume was optimized for particle size. 
Increase in the aqueous phase was observed to cause a corresponding increase in the total 
particle size. A volume of 400 μL of inner aqueous phase increased the particle size by 
around 30 nm i.e. 153 nm compared to that obtained with 200 μL of inner aqueous phase, 
which was 115.7 nm. 
2.4.4. Influence of process parameters  
Sonication helps in the emulsifying process, causing further size reduction of nanoparticle 
formulations[50]. Sonication time was optimized for total sonication times of the two 
cycles. The optimum sonication time was found to be 8 min for emulsion preparation as 
it showed the optimum particle diameter and good surface potential of 118 ± 2.01nm and 
-32.2 ± 1.5mV respectively. Solvents are used to dissolve the lipids in the oil phase in 
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emulsion preparation. Dichloromethane was found optimal for our study. However, 
solvents must be removed in the final preparation to eliminate any additional solvent-
induced toxicity. In solvent evaporation, the emulsion can stir for adequate amount of 
time to allow for effective removal of solvents by evaporation. The particle size was found 
to increase with longer stirring times. This may be due to the aggregation of particles post 
solvent-evaporation. A stirring time of 2 h was found to be optimum for preparation.  
 
 
 
Fig 2.3: Particle size distribution of a) blank solid lipid nanoparticles and b) EGCG-loaded solid 
lipid nanoparticles (EGCG-SLN), measured by dynamic light scattering. 
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Table 2.1: Optimization of formulation parameters for the preparation of solid lipid nanoparticles 
by the double-emulsification method 
Code Parameter  Particle 
diameter 
(nm) 
PDI ZP (mV) 
F1 
Type of lipid 
 
GMS* 121.4 ± 2.6 0.131 ± 0.07 -28.3 ± 3.4 
F2 Tripalmitin 133.8 ± 2.7 0.289 ± 0.17 -29.4 ± 0.9 
F3  Tristearin 131.1 ± 2.0 0.284 ± 0.2 -23.8 ± 3.04 
F4 Lipid: co-lipid 
ratio 
70:30 225.3 ± 2.4 0.452 ± 0.22 -33.8 ± 2.9 
F1 (GMS:SA) 80:20* 125.7 ± 2.7 0.128 ± 0.06 -30.4 ± 1.7 
F5  90:10 134.2 ± 1.7 0.234 ± 0.12 -32.5 ± 1.8 
F6 Surfactant used PVA 175 ± 3.9 0.411 ± 0.24 -4.23±2.01 
F7  Tween 80 153.6 ± 3.4 0.345 ± 0.26 -21.8 ± 3.4 
F1  Poloxamer F68* 127.5 ± 2.4 0.237 ± 0.15 -30.4 ± 2.4 
F8 Concentration of 
surfactant (%) 
1 133.7 ± 3.7 0.154 ± 0.01 -29.7 ± 2.8 
F1 2* 122.3 ± 3.4 0.157 ± 0.12 -24.5 ± 1.6 
F9  3 132.6 ± 2.6 0.264 ± 0.21 -31.1 ± 2.9 
F10 Amount 10 133.4 ± 2.3 0.128 ± 0.1 -30.9 ± 1.5 
F11 of co-emulsifier 15 127.1 ± 1.0 0.313 ± 0.22 -28.6 ± 3.4 
F1 (Soya lecithin) 20* 124.5 ± 1.6 0.294 ± 0.26 -35.1 ± 3.2 
F12 mg 30 130.4 ± 3.8 0.314 ± 0.21 -27.4 ± 2.3 
F1 Inner aqueous 
phase volume 
(µL) 
200* 115.7 ± 2.2 0.131 ± 0.1 -32.3 ± 1.6 
F13 300 135.2 ± 2.3 0.186 ± 0.11 -35.1 ± 2.4 
F14 400 153 ± 2.3 0.161 ± 0.14 -32.8 ± 1.8 
 
*denotes the optimized formulation 
GMS: Glyceryl mono-stearate; SA: Stearic acid; PVA: Polyvinyl alcohol 
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2.4.5. Encapsulation efficiency of EGCG-SLN  
After optimising the nanoparticles for process and formulation parameters, they were 
further optimised for the amount of drug loaded in the nanoparticles. EGCG was 
dissolved in the inner aqueous phase of the double emulsion and the rest of the procedure 
for preparation remained the same as that of the blank nanoparticles. EGCG-SLNs were 
prepared by keeping the lipid concentration constant at 5% w/v and varying the 
concentration of EGCG between 3% w/w and 5% w/w with respect to the lipid (Table 
2.2). The results showed that an increase in the concentration of the lipid led to an increase 
in the drug loading and hence the encapsulation efficiency. SLN with 5% w/w of drug 
showed an encapsulation efficiency of 67.2% and particle size of 157 ± 2.5 nm, hence 
was chosen as the optimum for future preparations (Fig. 2.3). Higher loading of drug was 
not possible due to super-saturation of the drug in the limited inner aqueous volume.  
Table 2.2: Optimization of encapsulation of epigallocatechin gallate (EGCG) in solid lipid 
nanoparticles 
EGCG to lipid 
ratio (%w/w) 
Particle size 
(nm) 
Polydispersity 
index (PDI) 
Zeta potential 
(mV) 
% EE 
3 112.5 ± 3.1 0.14 ± 0.12 -30.1 ± 3.2 89.5 ± 4.7 
4 128.2 ± 4.3 0.132 ± 1.21 -31.5 ± 3.7 75.8 ± 2.3 
5 157.4 ± 2.5 0.268 ± 0.14 -37.2 ± 2.5 67.2 ± 4.5 
PDI: Polydispersity index; ZP: Zeta potential; EE: Encapsulation efficiency 
2.4.6. Physico-chemical characterization  
2.4.6.1. FTIR analysis  
Infrared spectroscopy was used to determine the compatibility of drug with the 
components of the nanoparticles (Fig 2.4)[51]. The FTIR spectrum of EGCG shows a 
characteristic peak at 3356 cm−1 for the O-H group attached to the aromatic ring, a strong 
peak at 1691 cm−1 for the C=O group that links the trihydroxybenzoate group and 
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chroman group, and a peak at 1543 cm−1 for the C-C stretch in aromatic ring. Blank SLN 
shows a broad peak at 3347 cm−1 for the O-H stretching in glycerol mono-stearate which 
is one of the bulk components of the lipid core. It also shows a strong peak at 2917 cm−1 
for the O-H stretch and at 1737 cm−1 for the C-O stretch in carboxylic group in stearic 
acid. It also shows a peak at 1456 cm−1 for the C-H bending in alkanes. EGCG-SLN also 
shows peaks at 3358 cm−1 for the O-H stretching in GMS, peaks at 2917 cm−1 for the O-
H stretch and 1731 cm−1 for the C-O stretch in stearic acid and at 1468 cm−1 for the C-H 
bend in alkanes. Thus, EGCG post-encapsulation in SLN did not interact chemically and 
hence, is compatible with the excipients. 
 
 
Fig 2.4: Fourier transform infrared (FTIR) spectra of epigallocatechin gallate (EGCG), blank solid 
lipid nanoparticles (Blank SLN) and EGCG -loaded solid lipid nanoparticles (EGCG-SLN) 
2.4.6.2. DSC analysis  
The physical state of EGCG as a free drug and encapsulated as EGCG-SLN was 
determined by DSC analysis (Fig. 2.5). DSC analysis for Blank SLN shows a sharp peak 
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at 74 °C for melting point of stearic acid in blank formulation. The DSC thermogram of 
pure EGCG showed an endothermic peak at 224°C which corresponds to its melting 
point. This peak was not observed in EGCG-SLN suggesting the conversion of the 
crystalline form of drug into an amorphous, disordered crystalline or solid solution 
state[52]  
It indicates that the drug was solubilized inside the lipid matrix of EGCG-SLN. The peak 
for GMS appears at 62.5 °C which is close to its melting point of 59 °C. This peak, 
however, showed a broad shouldering. This can be attributed to the fact that lipids behave 
differently in bulk, native form and in the form of SLN formulation[53,54]. The shift in 
melting point can be explained by the fact that the small particle size of SLN results in 
high surface energy[44,55]. Also, lattice defects are created during preparation of SLN 
which leads to decrease in the crystallinity of the lipids being used[47]. These less ordered 
crystalline or amorphous solids require less energy to melt than pure crystalline 
substances and show a broad and less intense peak[56].  
 
Fig 2.5: Differential scanning calorimetric analysis of epigallocatechin gallate (EGCG) and EGCG 
loaded solid lipid nanoparticles (EGCG-SLN) 
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2.4.7. In-vitro drug release studies  
In-vitro release of EGCG from EGCG-SLN was studied in SAB at pH 5 to determine the 
pattern of release of drug from the nanoparticles. Fig. 2.6 shows the drug release pattern 
of EGCG-SLN. About 10% of encapsulated drug was released in the first hour increasing 
to 83.9% after 12 h and complete drug release (>90%) after 24 h. The sustained release 
of the EGCG from EGCG-SLN could be attributed to release of the drug by diffusion or 
erosion of the lipid nanocarriers[57,58]. Fangueiro et al. (2014) suggested that 
hydrophilic drugs are released from lipid nanoparticles by erosion or metabolization of 
the constituent lipids making up the nanoparticle shell[58]. Interestingly, because of the 
pH-dependent stability of EGCG (unstable at neutral pH while stable at acidic pH), 
EGCG-SLN could be a potential formulation for the delivery of EGCG to cancer cells in-
vivo. The drug released during its transport through the blood stream will degrade and 
only the drug reaching to the cancer cells through endocytosis of the nanoparticles will 
be effective. The system thus shows promise in reducing toxicity of EGCG in normal 
cells. 
 
Fig 2.6: In vitro drug release studies of EGCG loaded solid lipid nanoparticles (EGCG-SLN) in 
sodium acetate buffer pH 5 (Mean ± SD, n=3) 
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2.4.8. In-vitro cytotoxicity studies  
The in-vitro anti-cancer efficacy of pure EGCG, blank SLN and EGCG-SLN was 
investigated by anti-proliferation assay against two cancer cells i.e. MDA-MB 231 and 
DU-145 cells. Fig. 2.7 shows the % cell viability of MDA-MB 231 cells (Fig. 2.7a) and 
DU-145 cells (Fig. 2.7b) after incubation with blank SLN, EGCG and EGCG-SLN in a 
concentration range of 10–100 μg/mL for 24 hours. In the case of Blank-SLN, cell 
viability in both cancer cell lines was more than 90% at all tested concentrations which 
indicated its high biocompatibility and non-toxicity. After treatment with EGCG, cell 
viability in both cancer cells (MDA-MB-231 and DU-145) does not decrease 
substantially with an increase in EGCG concentration. However, EGCG-SLN showed a 
rapid decline in the viability of cancer cells. The cell viability of MDA-MB-231 was 
77.07% after treatment with 10 μg/mL of EGCG which progressively decreased to 
42.96% viability at the maximum concentration. 
 
Fig 2.7a 
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Fig 2.7b 
Fig 2.7: Percent cell viability of (a) MDA-MB-231 human breast cancer cells and (b) DU-145 
human prostate cancer cells after 24 h of treatment with pure epigallocatechin gallate (EGCG), 
blank solid lipid nanoparticles (blank SLN) and EGCG-loaded SLN (EGCG-SLN) 
In EGCG-SLN, in contrast, cell viability was found to be 46.65% and 3.12% at 10 μg/mL 
and 40 μg/mL of EGCG-SLN, respectively. In a concentration beyond 40 μg/mL, there 
was no viability seen in MDA-MB-231. A similar pattern was observed in DU-145, 
wherein EGCG displays no change in cell viability up to 40 μg/mL beyond which there 
was reduction in cell viability with increasing EGCG concentration, finally giving a cell 
viability percentage of 60.41% at the highest concentration (100 μg/mL). EGCG-SLN 
showed a remarkable decrease in cell viability of DU-145 as well. About 86.27% of DU-
145 cells were viable in the minimum test concentration (10 μg/mL) and 16.9% viable 
cells present at the 100 μg/mL. Observed IC50 values for EGCG and EGCG-SLN was 
78.9 ± 4.3 μg/mL and 9.7 ± 0.6 μg/mL against MDA MB-231 and 126.74 ± 3.4 μg/mL 
and 33.23 ± 0.7 μg/mL against DU-145 (Table 2.3). EGCG-SLN was 8.1 times more 
cytotoxic than EGCG against MDAMB-231 and about 3.8 times more cytotoxic against 
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DU-145. This increased cytotoxicity of EGCG-SLN in cancerous cells can be harnessed 
in future in-vivo applications as tumours are often characterized by a defective, leaky 
vascular architecture because of the poorly regulated nature of tumour angiogenesis and 
the interstitial fluid within a tumour is usually inadequately drained by a poorly formed 
lymphatic system. All of these factors contribute towards enhanced extravasation and 
selective retention of sub-micron particles within tumour tissues[59]. This phenomenon 
is called the enhanced permeation and retention (EPR) effect which is can be extensively 
used by nanoparticle systems like EGCG-SLN for passive targeting in cancer therapy.  
 
Table 2.3: IC50 values (µg/mL) for epigallocatechin gallate (EGCG) and EGCG-loaded solid lipid 
nanoparticles (EGCG-SLN) against MDA-MB-231 human breast cancer cells and DU-145 human 
prostate cancer cells after 24 h of treatment 
 
Formulation 
 
MDA-MB-231 DU-145 
EGCG 78.9 ± 4.3 126.7 ± 3.4 
EGCG-SLN 9.7 ± 0.6 33.2 ± 1.5 
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Fig 2.8a 
 
Fig 2.8b 
Fig 2.8: Phase contrast microscopy images of (a) MDA-MB-231 human breast cancer cells and (b) 
DU-145 human prostate cancer cells after 24 h of treatment with blank solid lipid nanoparticles 
(blank SLN), pure epigallocatechin gallate (EGCG), or EGCG-loaded SLN (EGCG-SLN) 
equivalent to 20 μg/mL EGCG. 
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Fig. 2.8 shows phase contrast images of control cells, cells treated with pure EGCG, blank 
SLN or EGCG-SLN after 24 h incubation. Fig. 2.8a and 2.8b show MDA-MB 231 and 
DU-145 cells treated with the above formulations, respectively. The cell morphology in 
MDA-MB 231 and DU-145 control cells is characterized by elongated epithelial cells. A 
change in morphology from elongated to spherical and cell shrinkage was visible in both 
the cell lines treated with EGCG and EGCG-SLN. However, a greater amount of cell 
shrinkage was visible in cells treated with EGCG-SLN suggesting greater cytotoxicity in 
the EGCG-SLN formulation compared to pure EGCG in agreement with the results in 
Fig. 2.7.  
2.4.9. Apoptosis studies 
Apoptosis of EGCG-SLN and EGCG in MDA-MB-231 and DU-145 cells was studied 
using the nucleus staining dye Hoechst 33342. The cells were treated with EGCG and 
EGCG-SLN for 24 h and then stained with Hoechst 33342 (Fig. 2.9). Nuclear 
fragmentation and apoptotic bodies were observed at a magnification of 10x with a scale 
of 100 µm. Untreated or control cells exhibited spherical and intact nuclei. Cells treated 
with EGCG-SLN showed more apoptotic bodies (32.7% in MDA-MB-231 and 24.9% in 
DU-145) and nuclear shrinkage compared to the EGCG-treated cells (14.5% in MDA-
MB-231 and 11.8% in DU-145) which are consistent with the results from the anti-
proliferation assay (Section 2.4.7.), thus proving that encapsulation in SLN facilitated 
greater anti-cancer efficiency and hence enhanced apoptosis of EGCG.  
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Fig 2.9a 
 
Fig 2.9b 
Fig 2.9: Nuclear fragmentation studies: Florescent microscopic images of (a) MDA-MB-231 human 
breast cancer cells and (b) DU-145 human prostate cancer cells after 24 h of treatment with blank 
solid lipid nanoparticles (blank SLN), pure epigallocatechin gallate (EGCG), or EGCG-loaded SLN 
(EGCG-SLN) equivalent to 20 μg/mL EGCG followed by staining with Hoechst 33342 
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2.4.10. Colloidal stability studies 
2.4.10.1. Stability of NPs in serum and physiological conditions  
The colloidal stability of the nanoparticles was determined in distilled water and PBS and 
expressed as a change in the particle size and zeta potential with time (Fig. 2.10). After 
intravenous administration, the size and charge of the nanoparticles are mainly 
determined by the adsorbed serum components[60]. Hence, a similar study was also 
carried out in rat serum. Particle size in distilled water remains constant with the size of 
112 nm at 0 h and 118.5 nm at 4 h. As expected, an initial increase in size (189.1 nm) in 
EGCG-SLN is observed in serum owing to the adsorption of serum proteins, subsequently 
falling to 134.3 nm at 2 h, following gradual protein desorption[61]. 
Particle size increases to 154.3 nm at the end of 8 h and 207 nm at 24 h. Particle size in 
PBS increases from 112 nm to 247.15 nm at 2 h, after which it stays constant. Zeta 
potential values for EGCG-SLN in distilled water remain constant with negative 
potentials of −30.3, −28.4, −32.3, −28.9, −31.3 and −29.5 mV at 0, 1, 2, 4, 8 and 24 h 
respectively. In PBS, the surface potential is −16.2, −19.2, −12.3, −10.7, −16.2 and −17.4 
mV at 0, 1, 2, 4, 8 and 24 h, respectively. The reduced negative potential of the 
nanoparticle suspension may be attributed to electrostatic interaction of opposite ions 
present in PBS. Surface potential in serum was −7.01, −7.39, −4.43, −7.64, −6.99 and 
−7.17 mV at 0, 1, 2, 4, 8 and 24 h, respectively. The reduced negative potential of EGCG-
SLN after exposing to serum may be due to the cumulative surface charges caused by the 
adsorption of serum proteins and other serum components[62]. 
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Fig 2.10a 
 
 
Fig 2.10b 
Fig 2.10: Change in (a) particle size and (b) zeta potential of EGCG-loaded solid lipid nanoparticles 
(EGCG-SLN) with respect to time. 
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2.4.10.2. Electrolyte induced aggregation  
Electrolyte-induced aggregation method  is used to determine the resistance of 
nanoparticles against flocculating agents[63]. EGCG-SLN were prepared by using 
Poloxamer 188 as a surfactant. Coating with surfactants provides a hydrophilic surface to 
the nanocarriers vehicle reducing the binding of opsonins and cells of the reticulo-
endothelial system[64]. EGCG-SLN show a high negative zeta potential which helps to 
stabilize nanoparticles in the dispersion by electrostatic repulsion (Fig. 11). The addition 
of electrolytes caused disturbances in this steric barrier resulting in particle aggregation. 
EGCG-SLN showed a steady increase in absorbance with an increase in sucrose sulphate 
concentration. Particle absorbance is constant until a concentration of 1.2 M after which 
an abrupt increase in absorbance was observed at concentrations of 1.4 M and higher. 
This suggests that EGCG-SLN are stable through electrostatic repulsion up to a 
concentration of 1.2 M sucrose sulphate after which excess electrolyte causes disruptions 
in the electrical double layer leading to increased flocculation. 
 
Fig 2.11: Effect of flocculating agent (sucrose sulphate) on the stability of EGCG loaded solid lipid 
nanoparticles 
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2.5. Conclusions  
In summary, EGCG loaded solid lipid nanoparticles were formulated to improve the 
stability and anti-cancer activity of EGCG. SLNs were prepared by a double-
emulsification method and optimized to provide nanoparticles with a particles size less 
than 200 nm and high drug encapsulation efficiency. EGCG-SLN showed significantly 
increased stability of encapsulated EGCG which was unstable at physiological conditions 
and showed complete degradation in pure form. In-vitro cytotoxicity studies showed that 
EGCG-SLN caused an 8.1fold increase in cytotoxicity of EGCG against MDA-MB-231 
cells and 3.8 times increase against DU-145 cancer cells. Further, in colloidal stability 
studies, EGCG-SLN showed stability in both serum and PBS and high resistance to 
electrolyte-induced aggregation. Therefore, EGCG-SLN can be considered a promising 
system for delivering EGCG as a potential chemotherapeutic agent. 
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3.1. Background 
In 2012, an estimated 14.1 million new cases of cancer occurred worldwide. Four of the 
most common cancers occurring worldwide are lung, female breast, bowel and prostate 
cancers, together constituting around 40% of all the cancer cases[1]. Breast cancer is the 
most frequent cancer in women, with 1.67 million cases diagnosed in 2012, accounting 
for one in four of all cancer cases in the world for women[2].  
Although many different chemotherapy drugs and drug regimens have been explored for 
the treatment of cancer, the disadvantages of non-specificity with cytotoxic drugs have 
to be circumvented to reduce non-specific organ damage[3]. The dissipation of the drug 
in other areas also results in the concomitant increase in drug dosages, as the intended 
organ may not get the total therapeutic dose required[4].   
Active targeting involves the attachment of ligands specific to factors overexpressed in 
cancer[5] to the nanoparticle. This leads to more accurate delivery as only cancer cells 
will receive the cytotoxic drug. Active targeting is therefore being explored in order to 
overcome the significant shortcomings associated with traditional chemotherapy. Gastrin 
releasing peptide receptor (GRPR) has been observed to be overexpressed in a variety of 
cancer types such as prostate, breast, cervical, glioblastomas, small cell lung cancer, 
gastric, pancreatic, and colon cancers[6]. It was therefore used as a cancer marker in this 
work. GRPR is a glycoprotein receptor (Chapter 1; Fig 1.9) with 7 transmembrane 
domains consisting of 384 amino acids[7].  
 
Fig 3.1: Structure of Bombesin 
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Bombesin (BBN) was the targeting ligand used in this study towards GRPR targeting. 
BBN is a 14 amino acid peptide with very high affinity to the gastrin releasing peptide 
receptor[8]. It was originally isolated from the skin of the toad Bombina bombina.  
Bombesin is the amphibian analog to GRPR’s natural ligand mammalian gastrin releasing 
peptide (GRP). GRP is a 27 amino acid peptide which shares a homologous C-terminal 
seven amino acid long sequence Trp-Ala-Val-Gly-His-Leu-MetNH2 with bombesin[9]. 
This sequence has been reported to be important for receptor binding and ligand 
internalisation via clathrin-mediated endocytosis[9]. Therefore, BBN is taken up by 
GRPR with the same mechanism as in its interaction with gastrin-releasing peptide.  
In this study, bombesin was conjugated to the EGCG-encapsulated SLN system that was 
optimised in Chapter 2 (Please refer to Section 2.3.2.). BBN-conjugated solid lipid 
nanoparticles were then explored for their anti-cancer efficacy, examining whether the 
addition of a targeting ligand enhances the anti-cancer potential. In-vivo studies on 
C57BL6 mice were performed to evaluate changes in tumour volumes and survivability 
in comparison to control animals. 
3.2. Materials 
Glycerol mono-stearate (GMS) was purchased from Alfa Aesar (Johnson Matthey 
Chemicals, Hyderabad, India). EGCG, bombesin, Pluronic F68 (P F68), Roswell Park 
Memorial Institute (RPMI)-1640 medium, fetal bovine serum (FBS), trypsin–EDTA, 
phosphate buffered saline (Ca2+, Mg2+ free), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were purchased from Sigma 
Aldrich (St. Louis, MO, USA). Soya lecithin was purchased from HiMedia (Mumbai, 
India). MDA-MB-231 human breast cancer cells, DU-145 (prostate cancer), A549(lung 
cancer), HEK-293 (embryonic kidney) and L-132 lung cell lines were obtained from 
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American Type Culture Collection (ATCC, Manassas, USA). Dichloromethane was 
obtained from Merck Chemicals (Mumbai, India). Tween 80 was purchased from sd Fine 
Chemicals Limited (Hyderabad, India). 
3.3. Methods 
3.3.1. Preparation of nanoparticles 
Solid lipid nanoparticles were prepared by the solvent emulsification-evaporation method 
as explained in Chapter 2 (Section.2.3.3.). Briefly, 80 mg glycerol mono-stearate, 20 mg 
stearic acid and 20 mg soya lecithin were dissolved in 2 mL of dichloromethane. The 
inner aqueous phase containing dissolved EGCG was added to this organic phase 
followed by 3 mL of 2% Pluronic F68 solution under sonication at 65% amplitude to 
form a primary water-in-oil (w/o) emulsion. This emulsion was added to 7 mL of 2% 
Pluronic solution to give a water-in-oil-in-water (w/o/w) emulsion. The nanoparticle 
suspension was allowed to stir for 2 hours for evaporation of the solvent and further 
centrifuged to precipitate out nanoparticle pellets. The supernatant was used for 
evaluation of entrapment efficiency.   
3.3.2. Calculation of entrapment efficiency 
The drug entrapment efficiency (EE) was calculated by the indirect method as previously 
mentioned in Chapter 2 (Section 2.3.3.). Briefly, the supernatant after centrifugation of 
the nanoparticle suspension was used for estimation of the free drug content by 
UV/Visible spectroscopy at the absorption maxima of EGCG at 274.5 nm. The percent 
entrapment efficiency was calculated by the following formula: 
 
% 𝐸𝐸 =
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐸𝐺𝐶𝐺 𝑎𝑑𝑑𝑒𝑑 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐸𝐺𝐶𝐺 𝑖𝑛 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝐸𝐺𝐶𝐺 𝑎𝑑𝑑𝑒𝑑
 ×100 
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3.3.3. Bioconjugation  
Conjugation, in this work, involves the formation of an amide bond between the peptide 
ligand and the lipid excipients of the nanoparticle matrix. Conjugation of bombesin to the 
drug loaded nanoparticles was carried out by the EDC-NHS method as described 
below[10].  
1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) is a cross linking 
agent used to couple carboxylic acids to primary amines. EDC reacts with a carboxyl 
group of the molecule to form an unstable amine-reactive O-acylisourea intermediate. 
This could also react with a primary amine to give a stable amide bond, but the instability 
of the O-acylisourea intermediate does not allow efficient coupling. If this intermediate 
does not encounter an amine, it will hydrolyse and regenerate the carboxyl group. 
Addition of sulpho-NHS helps to improve the stability of the intermediate to allow 
reaction with the primary amine[11] Sulpho NHS (N-hydroxysulfo succinimide) reacts 
with the acylisourea intermediate to form a more stable amine reactive NHS ester, which 
can now react with the primary amine leading to the formation of a stable amide bond[11]. 
 
Fig 3.2: Mechanism of the EDC-NHS reaction (Reproduced with permission from Pierce et al.) 
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Briefly, the nanoparticle suspension was incubated with 15 mg N-hydroxysuccinimide 
(NHS) and 20 mg N-(3-dimethylaminopropyl)-N-ethyl carbodiimide hydrochloride 
(EDC). The mixture was allowed to stir for one hour in an inert nitrogen atmosphere. 
Bombesin (0.25 mg) was added to this and further allowed to stir for 4 hours. The reaction 
was carried out in the presence of MES buffer (pH 6.2). Conjugation of bombesin to the 
lipid nanoparticles has been found to be optimum around pH 6.2 based on previous studies 
[12].  
The nanoparticle dispersion was collected and centrifuged at 10,000 rpm for 10 min and 
washed twice with distilled water. The supernatant was collected to estimate the 
conjugation efficiency using a standard Bradford protein assay. The amount of bombesin 
in the supernatant gives the amount of peptide not conjugated to the nanoparticles. A 
calibration curve in the range of 0.5–10 g/mL was prepared using a standard BSA stock 
solution (2 mg/mL). The supernatant was diluted appropriately and the absorbance was 
measured spectrophotometrically at 595 nm to determine the concentration of bombesin. 
3.3.4.  Physico-chemical characterization 
3.3.4.1. Particle size and surface charge 
The particle size and surface charge was determined by a Malvern Zetasizer using the 
protocol mentioned in Chapter 2 (Section 2.3.5.1.). Briefly, the mean particle size and 
zeta potential of blank nanoparticles (Blank SLN), EGCG-loaded SLNs (EGCG-SLN) 
and bombesin conjugated SLNs (EB-SLN) were measured by photon correlation 
spectroscopy using a Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., Malvern, 
UK). Samples were diluted 10 times with distilled water and analyzed at 25°C with a 
backscattering angle of 173°. 
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3.3.4.2. FTIR Analysis 
FTIR analysis of blank nanoparticles (Blank SLN), EGCG-loaded SLNs (EGCG-SLN) 
and bombesin conjugated SLNs (EB-SLN) was carried by potassium bromide (KBr) 
pellet method following the same protocol in Chapter 2 (Section 2.3.5.2.). Samples were 
scanned in the range of 400–4000 cm−1.  
3.3.4.3. DSC Analysis 
DSC analysis of EGCG-SLN and EGCG were carried out on a DSC1 instrument (Mettler 
Toledo, Switzerland) using the protocol mentioned previously in Chapter 2 (Section 
2.3.5.3.) 
3.3.5. In-vitro studies 
3.3.5.1. In-vitro cytotoxicity  
 MDA-MB-231 (breast cancer), DU-145 (prostate cancer), A549(lung cancer), HEK-293 
(embryonic kidney) and L-132 lung cell lines were grown in DMEM and RMI medium 
supplemented with 10% fetal bovine serum, 100 µg/mL penicillin, 200 µg/mL 
streptomycin and 2 mM L-glutamine. The cultures were maintained in a humidified 
atmosphere with 5% CO2. Dilutions were made with sterile PBS to get the required 
concentration. Formulations were filtered with a 0.22 µm sterile filter before adding to 
the wells containing cells. 
The cytotoxicity of formulations was determined by MTT assay based on mitochondrial 
reduction of yellow MTT tetrazolium dye to a highly coloured blue formazan product 
which shows absorption at 570nm[13]. 1 × 104 cells (counted by the Trypan blue 
exclusion dye method) in 96 well plates were incubated with EGCG-SLN, EB-SLN and 
pure EGCG with a series of concentrations for 48 h at 37 ºC in DMEM with 10% FBS 
medium. Then the above media was replaced with 90 µL of fresh serum free media and 
10 µL of MTT reagent (5 mg/mL) and the plates were incubated at 37 °C for 4 h. After 
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removing the media, 200 µL of DMSO was added and incubated at 37 °C for a further 
10 min. The absorbance at 570 nm was measured using spectrophotometer (Spectramax 
Plus, Molecular Devices, USA). 
3.3.5.2. Cellular uptake  
Rhodamine-B loaded nanoparticles (R-SLN) were prepared and conjugated with BBN 
(RB-SLN) for comparative cellular uptake studies. For quantitative studies, 1 × 105 cells 
per well were seeded in 12-well plates and allowed to adhere for 24 h. Cells were 
incubated with R-SLN and RB-SLN formulations for time intervals of 12 and 24 h. After 
removal of the culture media, the cells were washed twice with cold PBS and observed 
under a fluorescence microscope. 
3.3.5.3. Apoptosis assay  
Cell apoptosis was detected by assessment of nuclear morphology staining with Hoechst 
33342[14]. MDA-MB-231 cells were seeded in a 12-well culture plate at a density of 1 x 
105 cells per well and cultured at 37 ºC in a 5% CO2 incubator to obtain confluency. The 
cells were treated with EGCG, EB-SLN and EGCG-SLN formulation at a concentration 
of 20 μg/mL of EGCG and incubated for 24 hrs. After incubation the cells were washed 
with ice cold PBS twice, fixed with 4% paraformaldehyde in PBS (pH 7.4) for 15 min at 
room temperature, stained with 5 µg/mL Hoechst 33342 in PBS for 15 min and washed 
twice with ice cold PBS. The cells were then examined under fluorescence microscopy.  
3.3.5.4. Migration assay  
MDA-MB-231 (5 × 105 cells/mL) were seeded in petri dishes and allowed to grow to 
80% confluence. Wounds were created with sterile 250 μL pipette tips. Cells were 
incubated with EGCG, EGCG-SLN or EB-SLN, equivalent to 20 μg/mL EGCG. The 
zone of wound healing was observed at 0 and 24 h using a bright field microscope. The 
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percentage of wound closure was determined by measuring the wound area using Image 
J analysis software. 
3.3.6. Animal studies 
The animal experimental protocol for this study was approved by the Institutional Animal 
Ethics Committee of the CSIR-Indian Institute of Chemical Technology, Hyderabad 
(approval no. IICT/PHARM/SRK/FEB/2013/8). All the studies performed on the animals 
were in accordance with the guidelines of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA). Male C57/BL6 mice (6–8 weeks) 
weighing between 20–25 g were used for the survival studies. Animals were kept in 
polypropylene cages under standard laboratory conditions (12:12 h light/ dark cycle) at 
24 °C. The animals were housed five per cage and had free access to food and water. The 
mouse melanoma cancer cells B16F10 were grown and maintained in RPMI medium, 
supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin. Mice were 
injected with B16F10 cells (3 × 105 /mouse in 100 µL PBS) subcutaneously into the right 
flank via a 30G needle. The control group (PBS), EGCG group (1 mg EGCG/mouse), 
EGCG-SLN group (1 mg EGCG equivalent of EGCG-SLN/mouse) and EB-SLN (1 mg 
EGCG equivalent of EB-SLN/mouse) were tested in tumour-bearing mice. PBS, EGCG, 
EGCG-SLN and EB-SLN were administrated independently via intra-peritoneal injection 
every third day from day 14 after tumour implantation. The tumour size and body mass 
were measured regularly following the inoculation of tumour cells. Callipers were used 
to assess tumour growth by measuring two bisecting diameters in each tumour. The 
following equation was used to calculate the tumour volume: 
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Tumour volume (mm3) =
(width × length2) 
2
 
Scheme 3.1: Diagrammatic representation of the animal study methodology 
 
3.4. Results 
3.4.1. Particle size and surface charge 
Particle size and charge are important dimensions when constructing nanovehicles for in-
vivo applications. Nanoparticles within the size range of 6-200 nm show better tissue 
penetration and hence more efficient cargo delivery[15]. Surface charge of a particle 
determines the stability of the nanoparticles in the biological system. The greater the 
magnitude of the surface charge (i.e. strongly positive or strongly negative) the greater 
will be the repulsion with similar nanoparticles thus preventing aggregation and helping 
to sustain the nanoparticulate dimensions.  
Tumour cell 
Inoculation
•B16F10 mouse 
melanoma cells (3 x 
105/100 µL) injected in 
each mouse.
•Tumour develops in 12-
14 days
Formulation testing
Formulations 
administered 
intraperitoneally at a 
concentration of 50 mg 
EGCG/kg body weight 
every three days
Tumour 
regression 
and Survival 
Studies
Tumour volume will be 
evaluated at periodic 
time intervals.
Animals will be kept 
aside from each group 
for survival and dosage 
will be continued till 
natural death   
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Fig 3.3: Particle size distribution of a) blank solid lipid nanoparticles (Blank-SLN) b) EGCG-
loaded solid lipid nanoparticles (EGCG-SLN) and Bombesin conjugated solid lipid nanoparticles 
(EB-SLN), measured by dynamic light scattering 
 
 
Table 3.1: Particle size and surface charge for blank nanoparticles (Blank-SLN), EGCG-loaded 
SLN (EGCG-SLN) and bombesin conjugated SLN (EB-SLN) determined by dynamic light 
scattering 
Formulation Particle diameter 
(nm) 
Polydispersity index Zeta potential (mV) 
Blank-SLN 127.5 ± 2.4 0.227 ± 0.12 -30.4 ± 3.2 
EGCG-SLN 157.4 ± 2.4 0.182 ± 0.21 -37.5 ± 2.5 
EB-SLN 163.4 ± 3.2 0.341 ± 0.15 -25.2 ± 2.8 
 
(c) EB SLN 
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Blank nanoparticles showed a diameter of around 127.5 ± 2.4 nm with a PD index of 
0.227 ± 0.12 and a zeta potential of -30.4 ± 3.2 mV. The negative charges on the 
nanoparticles could be attributed to the carboxylate groups of the excipient lipids in the 
nanoparticle matrix. EGCG-SLN shows a particle size of around 157.4 ± 2.4 nm, a PD 
index of 0.182 ± 0.21 and a surface charge of -37.5 ± 2.5 mV. Bombesin conjugated EB-
SLN shows a particle size of 163.4 ± 3.2 nm with a PD index of 0.341 ± 0.15 and a zeta 
potential of -25.2 ± 2.8 mV. The surface potential has reduced from a more negative -
37.5 mV in EGCG-SLN to -25.2 mV in EB-SLN. This reduction in negative potential 
could be attributed to the masking of the negatively charged groups on the nanoparticle 
matrix. As more peptides get conjugated to the nanoparticle shell, more of the negative 
carboxylate groups of the charged lipids are neutralized by the formation of peptide 
bonds, thus reducing the total negative potential on the particle.  
3.4.2. FTIR analysis 
Infrared spectroscopy was used to determine the compatibility of the drug with the 
nanoparticle excipients. It also indicates the formation of a chemical bond between the 
lipids in the nanoparticle and bombesin (Fig 3.4). The FTIR spectrum of EGCG shows 
a characteristic peak at 3356.74 cm−1 for the O-H group attached to the aromatic ring, a 
peak at 1691.30 cm−1 for the C-O group that links the trihydroxybenzoate group and 
chroman group and a peak at 1543.88 cm−1 for the C-C stretch in the aromatic ring. The 
blank SLN shows a broad peak at 3347 cm−1 for O-H stretching in glycerol mono-stearate 
which is one of the bulk components of the lipid core. It also shows a strong peak at 2917 
cm−1 for the O-H stretch and a peak at 1737.88 cm−1 for the C-O stretch in the carboxylic 
group of stearic acid. It also shows a peak at 1456.05 cm−1 for C-H bending in alkanes. 
EGCG-SLN also shows peaks at 3358.08 cm−1 for O-H stretching in GMS, peaks at 
2917.17 cm−1 for the OH stretch and 1731.24 cm−1 for the C-O stretch in stearic acid and 
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at 1468.99 cm−1 for the C-H bend in alkanes. Thus, EGCG post-encapsulation in SLN 
did not interact chemically and hence, is compatible with the excipients. EB-SLN does 
not show the presence of peaks at 1730 cm−1 for carboxylic acid groups, suggesting the 
replacement of the carboxyl groups due to the formation of amide bonds with the amine 
group of bombesin. Furthermore, a prominent peak at 1640 cm−1 characteristic of amide 
C-N interaction is visible in the spectrum for EB-SLN. These changes point to the 
formation of amide bonds between the constituent lipids of the nanoparticle matrix and 
the peptide ligand.   
 
Fig 3.4: Fourier transform infrared (FTIR) spectra of epigallocatechin gallate (EGCG), blank solid 
lipid nanoparticles (BlankSLN), EGCG-loaded solid lipid nanoparticles (EGCG-SLN) and 
bombesin conjugated solid lipid nanoparticles (EB-SLN)  
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3.4.3. DSC analysis 
The physical state of EGCG as a free drug and encapsulated as EGCG-SLN was 
determined to evaluate whether EGCG was infact encapsulated within the SLNs (Fig. 
3.5). DSC analysis for EGCG-SLN shows a sharp peak at 62.4°C for the melting point 
of glycerol mono stearate in the EGCG-loaded formulation. The DSC thermogram of 
pure EGCG showed an endothermic peak at 224.4 °C which corresponds to its melting 
point. This peak was not observed in EGCG-SLN suggesting the conversion of the 
crystalline form of the drug into an amorphous, disordered crystalline state or a solid 
solution state[16]. It indicates that the entire drug was completely solubilized inside the 
lipid matrix of EGCG-SLN.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5: Differential scanning calorimetric analysis of epigallocatechin gallate (EGCG) and EGCG 
loaded solid lipid nanoparticles (EGCG-SLN) 
 
3.4.4. In-vitro studies 
3.4.4.1. In-vitro cytotoxicity 
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The in-vitro cytotoxicity of pure EGCG, EGCG-SLN and EB-SLN against MDA-MB-
231, A549, HEK-293 and L132 cell lines was evaluated by MTT assay. The cell viability 
of EGCG, EGCG-SLN and EB-SLN at a concentration range of 5-100 µg/mL was 
determined in MDA-MB 231 cells. The observed IC50 values for EGCG, EGCG-SLN and 
EB-SLN were 78.92 ± 4.3 µg/mL, 9.71 ± 0.6 µg/mL and 5.57 ± 3.2 µg/mL, respectively 
(Fig 3.6). The cell viability for EGCG was 42.94% at the highest tested concentration of 
100 µg/mL. For the EGCG-SLN formulation the cell viability was found to be 3.02% at 
100 µg/mL. Bombesin-conjugated EB-SLN showed a cell viability of 51.77% at the 
lowest concentration of 5 µg/mL, reducing drastically to 1.67% at a concentration of 40 
µg/mL and showing no cell viability at higher concentrations. The results indicate that the 
pure EGCG has low cytotoxicity in MDA-MB-231. However, its activity increased more 
than 8 times after encapsulation in SLNs and more than 14 times post conjugation with 
bombesin. For DU-145 cell line, the cell viability for maximum concentration of 
100µg/mL of EGCG was 60.4%, that for EGCG-SLN was 16.9% whereas for EB-SLN it 
was 7.7%.  The observed IC50 values for EGCG, EGCG-SLN and EB-SLN were 126.7 ± 
3.4 µg/mL, 33.2 ± 1.5 µg/mL and 19.2 ± 2.4 µg/mL respectively. For A549 cell line, the 
cell viability for maximum concentration of 100µg/mL of EGCG was 85.1%, that for 
EGCG-SLN was 20.4% whereas for EB-SLN it was 14.5%.  The observed IC50 values for 
EGCG, EGCG-SLN and EB-SLN were224.5 ± 3.9 µg/mL, 27.6 ± 4.5µg/mL and 24.8 ± 
3.8 µg/mL respectively. Of the three tested cancer cell lines, EB-SLN showed greater 
cytotoxicity in comparison with EGCG-SLN and EGCG in MDA-MB 231 cell line and 
hence this cell line was chosen for further studies. 
In addition, cytotoxicity evaluation was also carried out in two non-cancer cell lines HEK-
293 embryonic kidney and L132 lung cell lines. An interesting finding in this study was 
that EB-SLN was least toxic to these cells in comparison to EGCG-SLN and EGCG. The 
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observed IC50 values in HEK-293 for EGCG, EGCG-SLN and EB-SLN were19.6 ± 4.7 
µg/mL, 153.9 ± 2.5 µg/mL and 163.7 ± 4.1 µg/mL respectively. In L-132 cell line it was 
13.2 ± 2.3 µg/mL, 182.02 ± 3.4 µg/mL and 252.5 ± 3.7 µg/mL for EGCG, EGCG-SLN 
and EB-SLN respectively. These results point to selective specificity of formulation 
towards cancer cells as opposed to non-cancerous cells.    
 
 
 
 
Table 3.2: IC50 values (µg/mL) for epigallocatechin gallate (EGCG), EGCG-loaded solid lipid 
nanoparticles (EGCG-SLN) and bombesin conjugated SLN (EB-SLN) against MDA-MB-231, DU-
145, A549, HEK-293 and L-132 cells after 24 h of treatment 
 
Formulation 
 
MDA-MB-231 DU-145 A549 HEK-293 L132 
EGCG 78.9 ± 4.3 126.7 ± 3.4 224.5 ± 3.9 19.6 ± 4.7 13.2 ± 2.3 
EGCG-SLN 9.7 ± 0.6 33.2 ± 1.5 27.6 ± 4.5 153.9 ± 2.5 182.02 ± 3.4 
EB-SLN 5.5 ± 3.2 19.2 ± 2.4 24.8 ± 3.8 163.7 ± 4.1 252.5 ± 3.7 
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Fig 3.6: Percent cell viability of MDA-MB-231 human breast cancer after 24 h of treatment with 
pure EGCG, EGCG-loaded SLN (EGCG-SLN) and bombesin-conjugated EGCG-SLN (EB-SLN). 
 
 
Fig 3.7: Percent cell viability of DU145 prostate cancer cells after 24 h of treatment with 
pure EGCG, EGCG-loaded SLN (EGCG-SLN) and bombesin-conjugated EGCG-SLN (EB-SLN). 
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Fig 3.8: Percent cell viability of A549 prostate cancer cells after 24 h of treatment with pure EGCG, 
EGCG-loaded SLN (EGCG-SLN) and bombesin-conjugated EGCG-SLN (EB-SLN). 
 
Fig 3.9: Percent cell viability of HEK-293 kidney cells after 24 h of treatment with pure EGCG, 
EGCG-loaded SLN (EGCG-SLN) and bombesin-conjugated EGCG-SLN (EB-SLN). 
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Fig 3.10: Percent cell viability of L-132 lung cells after 24 h of treatment with pure EGCG, EGCG-
loaded SLN (EGCG-SLN) and bombesin-conjugated EGCG-SLN (EB-SLN). 
 
3.4.4.2. Phase contrast microscopy studies  
Phase contrast microscopy helps to microscopically observe changes to cell morphology. 
Fig 3.11 shows MDA-MB-231 cells treated with blank SLNs (Blank-SLN), EGCG, drug 
loaded EGCG-SLN and EB-SLN at 24 hours and 48 hours post treatment with the 
respective formulations. Control cells were used as negative controls in the experiment. 
When cells are under stress and undergoing apoptosis, a few distinct morphological 
changes can be seen. MDA-MB-231 cells are characteristically elongated and tapered. 
During cell death, the cell becomes spherical and apoptotic bodies can be seen with the 
help of a nuclear staining dye.  
Blank SLNs do not show any observable cytotoxicity, as is evident by the elongated 
healthy cells at 24 and 48 hours (Fig 3.11). The EGCG treated samples show apoptotic 
cells, demonstrated by the rounding of the cells when compared to the control cells at both 
time points. EGCG-SLN shows more spherical cells compared to EGCG which suggests 
greater toxicity. This could be attributed to the increased stability of the drug within the 
0
20
40
60
80
100
120
5 10 20 40 80 100
%
 v
ia
b
il
it
y
Concentration (μg/ml)
L132
EGCG
EGCG-SLN
EB-SLN
  
  105 
 
SLNs and also the sustained release due to encapsulation. EB-SLN shows more apoptotic 
cells, with the number of dead or dying cells increasing at 48 hours compared to 24 hours. 
This could again be attributed to the sustained release of the drug within SLNs and more 
importantly greater uptake due to targeting of bombesin to GRPR receptors. This 
enhanced uptake would automatically lead to increased concentrations of drug within the 
cell and hence, greater cytotoxicity, in agreement with the observations in Fig 3.6. 
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Fig 3.11: Phase contrast microscopy images of MDA-MB-231 human breast cancer cells after 24 h 
and 48 h of treatment with B) pure epigallocatechin gallate (EGCG), C) blank solid lipid 
nanoparticles (blank SLN), D) EGCG-loaded SLN (EGCG-SLN) and E) bombesin conjugated SLN 
(EB-SLN) equivalent to 20 μg/mL EGCG and A. control cells for reference.  
 
 
A 
B 
C 
D 
E 
24 h 48 h 
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3.4.4.3. Cellular uptake studies 
Uptake of nanoparticles by cancer cells was performed by loading a fluorescent dye in 
the lipid nanoparticle and observing fluorescence through microscopic detection. In this 
work Rhodamine B was chosen as the dye due to its hydrophilic nature, as the dye must 
be loaded in the same phase as that of the drug. Uptake was studied in the MDA-MB-231 
breast cancer cell line. Rhodamine-B loaded SLNs (RB-SLNs) were prepared in the same 
method as EGCG-loaded SLNs (Chapter 2, Section 2.3.3.) but with the drug replaced with 
Rhodamine-B dye. They were further conjugated with bombesin to give bombesin 
conjugated Rhodamine-B nanoparticles (RB-SLNs). An important advantage of targeting 
lies in the specificity it provides to the carrier vehicle. This increases the amount of drug 
delivered at the target site due to increased uptake via different mechanisms such as 
receptor mediated endocytosis; whereas passive targeting merely relies on EPR effect 
which does lead to sufficient uptake of nanoparticles but does not guarantee maximum 
payload delivery. The use of fluorescence to study uptake is a more visual way to 
determine differences in uptake. Fluorescence images were taken at two time points of 12 
and 24 hours (Fig 3.12). At 12 hours, visibly more intense red fluorescence is seen in cells 
treated with bombesin-conjugated nanoparticles compared with the unconjugated 
nanoparticles. At 24 hours, this difference is more pronounced with not only an increase 
in the fluorescence in the cells treated with RB-SLN, but there is also visible 
intensification of fluorescence in individual cells. These findings point to continual and 
increased uptake of nanoparticles in the cancerous cells conjugated with the targeting 
ligand bombesin as opposed to the unconjugated formulation.  
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Fig 3.12: Cellular uptake studies: Fluorescent microscopic images of MDA-MB-231 human 
breast cancer cells after 24 h of treatment with Rhodamine-loaded SLN (R-SLN) and 
bombesin conjugated SLN (RB-SLN)  
3.4.4.4. Apoptosis studies  
Apoptosis is a process of programmed cell death that occurs after a cell is no longer 
needed in the body. It occurs by two pathways, namely extrinsic and intrinsic pathways 
(Refer to Section 2.1.e.). In cancer cells, the factors affecting these two pathways are 
downregulated causing the cells to continue to proliferate uncontrollably. EGCG has 
shown the ability to induce apoptosis, as explained in Chapter 2. Nuclear condensation is 
an important process during apoptosis that forms the principle of the nucleus-staining 
apoptosis assay. Hoeschst 33342 was the dye used in this study. Hoeschst 33342 is a cell-
permeable, blue fluorescence dye. When this dye binds to DNA it emits blue fluorescence 
at 495 nm[14].  
To study apoptosis caused by the different formulations, MDA-MB-231 cells were 
incubated with blank-SLN, pure EGCG, EGCG-SLN and EB-SLN for 24 hours followed 
R-SLN RB-SLN 
12 
Hrs 
24 
Hrs 
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by staining with Hoeschst 33342. Fluorescence images in Fig. 3.13 clearly showed the 
difference in nuclear staining. Hoeschst 33342 stains all nuclei, hence blue fluorescence 
is visible throughout. However, the intensity of fluorescence is more in cells undergoing 
apoptosis, owing to nuclear condensation. Control cells and cells treated with blank-SLN 
show no intense fluorescence. However, EGCG does show several intense fluorescence 
specks. These specks increase in the EGCG-SLN, however the highest intensity is visible 
in the EB-SLN formulation treated cells. An explanation for this is that the cells show an 
increased uptake of these nanoparticles in comparison to the other samples due to the 
presence of the targeting ligand bombesin. This resulted in the successful delivery of 
increased concentrations of the cytotoxic EGCG inside the cells, thus causing a greater 
extent of apoptosis.    
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Fig. 3.13: Nuclear fragmentation studies: Fluorescent microscopic images of MDA-MB-231 human 
breast cancer cells after 24 h of treatment with blank solid lipid nanoparticles (blank SLN), pure 
epigallocatechin gallate (EGCG), EGCG-loaded SLN (EGCG-SLN) and bombesin conjugated SLN 
(EB-SLN) equivalent to 20 μg/mL EGCG followed by staining with Hoechst 33342. 
 
3.4.4.5. Migration studies 
Angiogenesis is the process by which a tumour develops new blood vessels from existing 
ones in order to maintain continual growth and nutrition. Therefore, inhibition of 
angiogenesis aids in preventing the growth and metastasis of tumours, by essentially 
cutting off its nutrition. EGCG has shown anti-angiogenic effects in a number of cell lines 
as mentioned in Chapter 2(Section 2.1). However, this effect was found to be increased 
when it was encapsulated as EGCG-SLN and further conjugated with bombesin (Fig 
3.14). Wound closure is found to more in control cells as compared to EGCG. Wound 
EGCG-SLN 
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closure is almost negligible in EGCG-SLN and EB-SLN. Enhanced activity in EGCG-
SLN and EB-SLN could be attributed to the increased stability of the drug within the 
solid lipid nanoparticles and hence greater activity. Sustained release of EGCG from the 
nanoparticles also aids in continued anti-migratory effect of the drug leading to better 
wound closure in EGCG- loaded nanoparticles than pure drug. 
 
Fig 3.14: Scratch assay images for MDA-MB-231 human breast cancer cells after 24 h of treatment 
with blank solid lipid nanoparticles (blank SLN), pure epigallocatechin gallate (EGCG), EGCG-
loaded SLN (EGCG-SLN) and and bombesin conjugated SLN (EB-SLN) equivalent to 20 μg/mL 
EGCG, along with control cells for reference 
 
3.4.5. In-vivo studies 
The in-vivo anticancer efficacy of a therapeutic agent is assessed in terms of prolonging 
the quality of life and increasing the survival time. The anti-tumour efficacy of EGCG, 
EGCG-SLN or EB-SLN was evaluated on tumour bearing mice upon administration of 
multiple doses equivalent to 50 mg/kg EGCG. In-vivo anti-tumour efficacy was evaluated 
in a syngeneic C57/BL6 mouse model. 
B16F10 cancer cell line was used to develop melanoma in this study. Gastrin-releasing 
peptide receptors are overexpressed in many cancers. B16F10 mouse melanoma cell line 
0 hr 
24 hr 
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shows expression of GRPR receptors and therefore was used for checking the efficacy of 
the bombesin conjugated formulation[17]. Mice were first injected subcutaneously with 
3 × 105 B16F10 cells on the flank to grow melanoma in- situ. Forty tumour bearing 
C57/BL6 mice were randomly divided into 4 groups (n=10) and intraperitoneally 
administered EGCG, EGCG-SLN or EB-SLN at a dose equivalent to 50 mg/kg body 
weight of EGCG every third day. The control group was administered an equivalent 
volume of saline every third day.  
The body weight, tumour volume and overall survival of the mice were recorded. The 
mean survival time was determined using a Kaplan-Meier survival plot (Fig 3.15). A 
mean survival of 41, 48 and 55 days were observed for EGCG, EGCG-SLN and EB-SLN 
treated mice, respectively, compared to control mice (37 days) which were administered 
with normal saline. There was a significant extension in the life span of mice treated with 
EB-SLN.  
The changes in body weight and tumour volume of the animals were also recorded during 
the whole experiment. The change in body weight is an indicator of systemic toxicity 
caused by the formulation[18]. There was rapid loss of body weight in the saline treated 
control group in comparison to EGCG formulation treated animals (Fig 3.16). The control 
group receiving only saline recorded a loss of 7.01% in total body weight in 30 days 
whereas both EGCG-SLN groups showed increase by 1.58% and EB-SLN, 1.06% loss of 
body weight, respectively. 
The change in tumour volume was also observed and results revealed that tumour shrank 
in the mice receiving EGCG formulation. The percent increase in tumour volume in mice 
treated with EGCG-SLN and EB-SLN was 3.78% and 0.78% respectively as compared 
to mice receiving pure EGCG and control which were 5.45% and 7.97% respectively. 
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Fig 3.15: Kaplan-Meier Plot for survival following administration of pure epigallocatechin 
gallate (EGCG), EGCG-loaded SLN (EGCG-SLN) and bombesin conjugated SLN (EB-SLN) 
formulations, with control mice for reference 
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Fig 3.16: Change in body weight and tumour volume in mice with the number of days 
following administration of pure epigallocatechin gallate (EGCG), EGCG-loaded SLN 
(EGCG-SLN) and bombesin conjugated SLN (EB-SLN) formulations with control mice for 
reference 
 
3.4.6. Conclusions 
Bombesin-conjugated nanoparticles were prepared by the double-emulsification solvent 
evaporation method followed by conjugation with EDC-NHS. FTIR analysis validated 
the formation of the amide bond between the carboxylic C-O group of the lipid with the 
free amino group of the peptide. IC50 values indicate that the pure drug EGCG has low 
cytotoxicity in MDA-MB-231, but its activity increased more than 8 times after 
encapsulation in SLNs and more than 14 times post conjugation with bombesin. 
Fluorescence uptake images show more uptake of RB-SLN compared to non-targeted R-
SLN at all time points. Migration studies show substantial inhibition by the targeted EB-
SLN formulation. Animal studies indicate that administration of EB-SLN led to greater 
survival rate in C57/BL6 mice in comparison to other formulations. These findings 
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suggest the merits of attachment of a targeting ligand to the EGCG-encapsulated SLN 
system in Chapter 2, further corroborating the potential of EGCG-encapsulated systems 
in cancer therapeutics. 
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nanoparticles for cancer therapy 
  
  120 
 
4.1. Background 
Phytochemicals are plant derived chemical compounds which have been used in ancient 
medicine in many parts of the world, with the first literature on their beneficial effects 
dating back to 2800 BC[1]. Phytochemicals consist of a wide class of chemical 
compounds which includes alkaloids, glycosides, flavonoids, volatile oils, tannins and 
resins[2]. They have been known to help in the treatment and prevention of many diseases 
such as cardiovascular disease, cancer, osteoporosis and hypercholesterolemia[3].  
In this chapter, two phytochemicals have been used to explore anti-cancer efficacy 
namely mangiferin and piperine. These formulations were chosen in order to investigate 
the use of SLNs with a targeted chemotherapeutic system. 
A. Mangiferin encapsulated solid lipid nanoparticles for targeting towards 
cancer  
Mangiferin (2-b-D-glucopyranosyl-1, 3, 6, 7-tetrahydroxyxanthone) is a C-glucoside 
xanthone found in many families such as Anacardiaceae, Bignoniaceae, Moraceae, 
Thymelaceae, Aphloiaceae, Malvaceae and Gentianaceae[4]. It is found in higher 
concentrations in the root, bark and leaves of Mangifera indica (mango) plant. 
Chemically it contains an aromatic ring attached to the C–C bond of a glucose moiety 
(Fig. 4.1.), making the molecule polar and water soluble[5]. 
Its many beneficial medicinal properties such as anti-oxidant, anti-diabetic, analgesic, 
anti-inflammatory, anti-hypertensive, immune-modulatory, neuro-protective, anti-viral,  
hypo-lipidemic and anti-cancer activities have been reviewed extensively[6–9]. 
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  Fig 4.1: Structure of mangiferin 
Mangiferin has been extensively researched for its anti-cancer properties, exerting anti-
cancer effects by a variety of mechanisms such as anti-inflammatory, anti-proliferative, 
apoptotic and immune-modulatory effects[10–12] outlined as follows:  
a. Anti-inflammation 
Inflammatory processes have been regarded as important contributors in the development 
of cancer. Factors such as NFκB (Nuclear factor kappa-B) and interleukins are 
overexpressed which are critical mediators of the immune responses that control the 
transcription of inflammatory cytokines[13]. Mangiferin downregulates the production of 
NFκB by blocking NF-κB and MAPK signalling pathways[14]. 
b. Proliferation/ metastasis 
In normal cells, the rate of cell division and cell death is strictly regulated to prevent 
anomalies. In cancer cells, however, the factors responsible for cell death are down-
regulated, causing cells to replicate uncontrollably. Loss of cell adhesion causes cancer 
cells to escape from the site of origin and migrate to other sites causing secondary 
cancers[15]. Mangiferin has been found to cause induction of miRNA-15b which is a 
factor whose upregulation causes cell cycle arrest in cancer cells in the G0/G1 phase, 
while simultaneously downregulating matrix metalloproteinase MMP-9, which is an 
important factor in the degradation of the basement membrane and metastasis[16]. 
c. Apoptotic effect 
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Apoptosis is a process of controlled cell death which occurs by two pathways; an extrinsic 
pathway which involves activation of death receptors or the intrinsic pathway which 
involves the increased permeability of the mitochondria[17]. Mangiferin was found to 
activate the intrinsic apoptotic pathway by upregulating caspase-9 cleavage and 
activation, which is an initiator caspase that cleaves and activates the executioner caspases 
(caspases 3 and 7), leading to apoptosis[18]. 
d. Immunomodulatory effects 
Cancer cells avoid detection by the body’s immune system by the expression of proteins 
that dampen the immune response. Mangiferin was found to increase the levels of 
immunoglobulins IgM and IgG in animals with benzo(a)pyrene-induced lung 
carcinogenesis[19]. 
In this work, mangiferin was encapsulated in solid lipid nanoparticles to study its anti-
cancer efficacy. The encapsulation was carried out by the single emulsion-solvent 
evaporation method. Stearic acid was used as a charge modifier along with glycerol 
mono-stearate as the matrix components. Bombesin was conjugated to this system as the 
ligand and the release characteristics of the system were studied.  
4.2. Materials 
Glycerol mono-stearate, stearic acid, Poloxamer F68, mangiferin, chloroform, 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide (NHS) and N-
[tris(hydroxymethyl)methyl]-2-aminoethane sulfonic acid (MES) were used as received. 
4.3. Methods 
4.3.1. Preparation of nanoparticles  
SLNs were prepared by the single solvent-emulsification and evaporation method. The 
oil in water emulsion of mangiferin was made by dissolving 5 mg of MgF in 2 mL 
chloroform and it was then emulsified slowly in 10 mL of 1.5% Tween 20 surfactant 
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solution. The emulsion was sonicated for 15 mins at 50% amplitude using a probe 
sonicator. It was stirred for 3 hours to allow for solvent evaporation and mangiferin-
loaded SLNs (MgF-SLNs) were then pelleted by centrifugation at 15000 rpm for 30 
minutes and stored for further work. The supernatant was used for determining the 
encapsulation efficiency. 
4.3.2. Determination of entrapment efficiency 
The entrapment efficiency of solid lipid nanoparticles to encapsulate mangiferin was 
calculated by the indirect method. The supernatant collected after centrifugation of MgF-
SLNs was used to determine the concentration of free mangiferin by UV-visible 
spectroscopy. A calibration curve of mangiferin was constructed and used for the 
calculation of unknown concentrations.   
4.3.3. Bioconjugation 
MgF-SLNs were conjugated with bombesin using EDC-NHS reaction. Briefly, the 
nanoparticle suspension was incubated with 15 mg N-hydroxysuccinimide (NHS) and 20 
mg N-(3-dimethylaminopropyl)-N-ethyl carbodiimide hydrochloride (EDC). The 
mixture was allowed to stir for an hour for the activation of the carboxylic acid groups of 
stearic acid in the SLN matrix. Bombesin (0.25 mg) was then added to this and further 
stirred for 4 hours to allow conjugation to take place. The reaction was carried out in the 
presence of MES buffer (pH 6.2) as the conjugation of bombesin to lipid nanoparticles 
has been found to be optimum around pH 6.2 based on previous studies[20].  
The bombesin–conjugated nanoparticles (MB-SLNs) were now centrifuged at 10,000 
rpm for 10 minutes to remove unconjugated peptide molecules. The supernatant was 
stored for calculation of the unconjugated peptide. 
4.3.4. Calculation of conjugation efficiency 
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Unconjugated peptide was calculated by the Bradford assay method for determination of 
protein. Briefly, a calibration curve for bombesin was plotted and the unknown 
concentration was calculated by spectrophotometric detection at 595nm.  
4.3.5. Physico-chemical characterization 
4.3.5.1. Particle size and surface charge 
Nanoparticles were optimized for particle size and surface charge. The mean particle sizes 
and zeta potentials of blank nanoparticles (Blank-SLN), mangiferin-loaded SLNs (MgF-
SLNs) and bombesin conjugated nanoparticles (MB-SLNs) were measured using a 
Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., Malvern, UK). Samples were 
diluted 10 times with double distilled water and analyzed at 25 ºC with a backscattering 
angle of 173º. Surface potentials for the formulations were also determined with the 
Zetasizer.. 
4.3.5.2. FTIR analysis 
FTIR analysis of Blank-SLN, MgF-SLN and MB-SLN was carried by using an IR 
spectrophotometer (Perkin Elmer, USA). Pellets were prepared by adding approximately 
3 mg of the sample to 100 mg of KBr. Samples were scanned in the range of 400–4000 
cm−1. 
4.3.6. In-vitro drug release 
In-vitro drug release studies were performed by dialysis in sodium acetate buffer pH 5 
(SAB) and phosphate buffer pH 7.4. MgF-SLNs, equivalent to 2 mg of mangiferin, were 
placed in dialysis tubing and kept in a beaker containing 100 mL of SAB and PBS and 
maintained at 37 ºC. At predetermined time intervals, 1 mL of buffer was withdrawn and 
replaced with same volume of fresh media to maintain sink conditions. The mangiferin 
concentration was determined by measuring the absorbance at 342 nm, which is the 
absorption maxima for mangiferin, using a UV/Visible spectrophotometer. 
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4.4. Results 
4.4.1. Preparation of nanoparticles 
Solid lipid nanoparticles were prepared by the emulsification-solvent evaporation method 
to form an oil-in-water emulsion. Mangiferin was dissolved in chloroform which was the 
inner organic phase. Tween 20 solution was used as the outer aqueous phase. 
Emulsification was carried out using a probe sonicator for 15 minutes. The formulation 
was optimized for particle diameter and charge for the surfactant used and its 
concentration. The lipids used and their concentrations were optimized earlier in Chapter 
2 (Section 2.4.2) Surfactants used for optimization included polyvinyl alcohol (PVA), 
Tween 20 and Poloxamer F68. Tween 20 gave a particle size of 100.2 ± 3.1 nm, while 
PVA and Poloxamer F68 gave a particle size of 132.5 ± 2.2 nm and 125.4 ± 3.6 nm, 
respectively. The polydispersity of the Tween 20 formulation (F2) was 0.185 ± 0.2, while 
that for PVA and Poloxamer 188 were 0.342 ± 0.2 and 0.379 ± 0.3, respectively. The 
particle size and polydispersity of F2 were considerably lower than that of the others and 
hence it was chosen to carry out further optimization. The concentration of Tween 20 in 
the aqueous phase was optimized between 1, 1.5 and 2% in aqueous solution. The particle 
size decreases with an increase in surfactant concentration with 1%, 1.5% and 2% Tween 
20 giving particle diameters of 117.7 ± 5.4 nm, 100.2 ± 3.1 nm and 96.5 ± 4.7 nm, 
respectively. This could be attributed to the fact that an increase in surfactant 
concentration increases particle repulsion hence giving better size and polydispersity 
measurements. However, the surface potential is found to decrease at 2% Tween 20 
concentration which could lead to a reduction in stability. Thus, 1.5% Tween 20 
formulation was chosen as the final formulation. 
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Table 4.1: Optimization of formulation parameters for Mangiferin-loaded solid lipid nanoparticles 
prepared by the single-emulsification method 
 
 
 
 
 
 
 
 
4.4.2. Determination of entrapment efficiency 
Formulation F2 chosen as the final formulation for optimization of drug loading and 
entrapment efficiency. Initially a calibration curve of mangiferin was plotted with UV-
Visible spectroscopy at the λmax of 315 nm. Three concentrations of mangiferin were 
evaluated for entrapment efficiency, which were 1, 3 and 5 mg of mangiferin.  
 
Fig 4.2: Calibration curve of Mangiferin 
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Formulation 
name 
Parameter Type Particle size 
(nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
F1 Surfactant PVA 132.5 ± 2.2 0.342 ± 0.2 -25.7 ± 2.6 
F2 used Tween 20 100.2 ± 3.1 0.185 ± 0.2 -24.9 ± 2.5 
F3  Poloxamer 
F68 
125.4 ± 3.6 0.379 ± 0.3 -21.6 ± 3.4 
F4 Concentration 1 117.7± 5.4 0.237 ± 0.3 -30.8 ± 2.3 
F2 Of 1.5 100.2 ± 3.1 0.185 ± 0.2 -24.9 ± 2.5 
F5 Surfactant 
(%) 
2 96.5 ± 4.7 0.126 ± 0.3 -17.7 ± 3.4 
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Table 4.2: Optimization of encapsulation of mangiferin and entrapment efficiency in mangiferin-
loaded SLN (MgF-SLN) 
 
 
 
 
 
 
 
 
 
Particle sizes for 1, 3 and 5 mg mangiferin loaded formulations were found to be 89.52 ± 
3.7 nm, 95.1 ± 4.1 nm and 100.2 ± 3.1 nm, respectively. Particle sizes were found to 
increase with an increase in the amount of drug, which could be attributed to an increase 
in the amount of drug assimilation between the crystallized lipid matrix therefore causing 
an increase on hydrodynamic diameter. Entrapment efficiency for 1, 3 and 5 mg were 
found to be 85.6 ± 3.7%, 81.4 ± 2.3% and 75.31 ± 2.3% for the F6, F7 and F2 
formulations, respectively (Table 4.2). However, the F2 (5 mg) formulation was chosen 
as even with a lesser entrapment efficiecy the total amount of drug loaded will be more 
in this case compared to the others (3.765 mg). 
4.4.3. Bioconjugation 
Bioconjugation of bombesin to MgF-SLN was carried out by the EDC-NHS method as 
explained in Chapter 3 (Refer Section 3.3.3.). EDC-NHS reaction helps to activate the 
carboxylic groups in the charge modifier lipid (stearic acid) in order to help easier 
formation of the amide bond between the carboxylate ion and the amine group of 
bombesin. The centrifuged bombesin-conjugated nanoparticle (MB-SLN) formulation 
was evaluated for particle size and surface potential. The zeta potential increased from   -
24.9 ± 2.5 mV of MgF-SLN formulation to -16.3 ± 2.4 mV in MB-SLN. This could be 
Formulatio
n name 
Parameter Type Particle size 
(nm) 
Polydispersity 
index 
Zeta 
potential 
(mV) 
Entrapmen
t efficiency 
(%) 
F6 Amount 1 89.52 ± 3.7 0.131 ± 0.2 -24.4 ± 2.1 85.6 ± 3.7 
F7 Of drug 3 95.1± 4.2 0.264 ± 0.4 -25.2 ± 2.3 81.4 ± 2.3 
F2 (mg) 5 100.2 ± 3.1 0.185 ± 0.2 -24.9 ± 2.5 75.31 ± 2.3 
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attributed to masking of the negative carboxylate groups due to bond formation and 
therefore a decrease in the total negative potential on the particle surface. 
4.4.4. Calculation of conjugation efficiency 
The conjugation efficiency of bombesin (BBN) was calculated by the indirect method. 
The amount of unconjugated Bombesin in the supernatant was quantified using the 
Bradford assay for protein determination[21]. The conjugation efficiency for 250 µg BBN 
was found to be 82.34 ± 2.53%. 
4.4.5. Physico-chemical characterization 
4.4.5.1. Particle size and surface charge 
The particle size and surface charge of (Blank-SLN), MgF-SLN and MB-SLN were 
observed by Malvern Zetasizer Nano ZS. The particle size of Blank-SLN, MgF-SLN and 
MB-SLN were 96.57 ± 2.8 nm, 100.2 ± 3.1 nm and 121.4 ± 4.2 nm, respectively (Table 
4.3). The increase in nanoparticle diameter from Blank SLN to MgF-SLN could be 
attributed to the diffusion of the drug between the crystalline lipid matrix therefore 
leading to an increase in size[22]. The zeta potential for Blank SLN and MgF-SLN was -
26.9 ± 3.1 mV and -24.9 ± 2.5 mV, respectively. There was not much change in surface 
potential suggesting that mangiferin was not adsorbed on the surface and was 
encapsulated. The particle size of the MB-SLN increases to 121.4 ± 4.2 nm which could 
be due to attachment of the ligand on the particle surface. Also, the zeta potential tends 
towards more positive value of -16.3 ± 2.4 mV in MB-SLN. This could be attributed to 
masking of the negative carboxylate groups by bond formation with bombesin molecules 
on the surface. 
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Table 4.3: Particle size distribution, polydispersity and zeta potential values for blank formulation 
(Blank-SLN), mangiferin-loaded SLN (MgF-SLN) and bombesin-conjugated MB-SLN formulations 
determined by dynamic light scattering 
 
 
 
 
 
 
              
                                      
Fig 4.3: Particle size distribution for the blank formulation (Blank-SLN), mangiferin-loaded SLN 
(MgF-SLN) and bombesin-conjugated MB-SLN formulations measured by dynamic light scattering 
 
 
Formulation 
name 
Particle size 
(nm) 
Polydispersity 
index 
Zeta 
potential 
(mV) 
Blank-SLN 96.57 ± 2.8 0.270 ± 0.1 -26.9 ± 3.1 
MgF-SLN 100.2 ± 3.1 0.185 ± 0.2 -24.9 ± 2.5 
MB-SLN 121.4 ± 4.2 0.324 ± 0.1 -16.3 ± 2.4 
Blank 
SLN 
MgF-SLN 
MB-SLN 
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4.4.5.2. FTIR analysis 
FTIR spectrum of mangiferin shows a peak at 3367 cm-1 indicating presence of secondary 
-OH bond (alcoholic OH), a peak at 2938 cm-1 for C-H anti-symmetric stretching and 
peaks at 2830 cm-1 and 1649 cm-1 indicating the presence of the C-H and C-O symmetric 
stretching. The blank SLN shows a broad peak at 3308 cm-1 for the O-H stretching in 
glycerol mono-stearate which is one of the bulk components of the lipid core. It also 
shows a peak at 2917 cm-1  for the O-H stretch and at 1730 cm-1 for the C=O stretch in the 
carboxylic group in stearic acid. It also shows a peak at 1456 cm-1 strong for the C-H 
bending in alkanes. Drug loaded MgF-SLN also shows peaks at 3307 cm-1 for the O-H 
stretching in GMS, peaks at 2917 cm-1 for the O-H stretch and 1730 cm-1 for the C=O 
stretch in stearic acid. The spectrum for mangiferin was different from the blank-SLN 
and MgF-SLN. The spectra for drug loaded MgF-SLN and blank-SLN were similar which 
shows that there were no unpleasant interactions between the drug and the lipid 
nanoparticle and it was encapsulated efficiently. 
Conjugated-SLN (MB-SLN) shows a broad peak at 3390 cm-1 for secondary alcoholic 
OH groups from stearic acid. The peak at 2917 cm-1 for the O-H stretching is also visible. 
However, peaks at 1645 cm-1 and 1707 cm-1 for amide linkage, which were not visible in 
the blank or MgF-SLN are prominent providing evidence for amide bond formation. 
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Fig 4.4 Fourier transform infrared (FTIR) spectra of for blank formulation (Blank-SLN), 
mangiferin-loaded SLN (MgF-SLN), mangiferin and bombesin-conjugated MB-SLN formulations 
 
4.4.6. In-vitro drug release 
The drug release of Mangiferin was evaluated in phosphate buffer saline (PBS-pH 7.4) 
and sodium acetate buffer (SAB-pH 5). MgF-SLN were placed in a dialysis membrane 
and allowed to stir in solutions of a fixed volume (100 mL) of PBS and SAB buffers. 
Aliquots of 1 mL were collected at regular intervals and the amount of mangiferin 
released was quantified by UV-Vis spectroscopy. 4 mg mangiferin was loaded in both 
formulations. 
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Fig 4.5: In- vitro drug release studies of mangiferin-loaded SLN (MgF-SLN) in sodium acetate 
buffer pH 5 and phosphate buffer (pH 7.4) 
 
Release data in PBS shows controlled release with 4.3 %  released in the first 15 minutes, 
16.8 % released at the end of 6 hours. In SAB, 4.4% was released in 15 minutes and 17.1 
% in 6 hours. At the end of 24 hours, around 77.5% of the drug is released while at 48 
hours, 94% of the drug was released. In SAB, 89.8% is released in the first 24 hours, 
while 96.77% is released at the end of 48 hours. The results show that there is gradual 
release in both pH conditions. Also, release is greater in SAB while compared to PBS, 
suggesting that there is greater release in an acidic environment such as the one found in 
cancer cells as compared to physiological blood pH. These findings provide promise that 
this system will be appropriate in physiological conditions such as those encountered in 
tumour tissue. 
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B. Piperine encapsulated chitosan nanospheres conjugated with mannose for 
glycotargeting towards lectin receptors overexpressed in cancer  
Pepper has been used as a spice in southeast Asian and European cuisines and medicine 
for a long time. Piperine ((2E,4E)-5-(2H-1,3-Benzodioxol-5-yl)-1-(piperidin-1-yl) penta-
2,4-dien-1-one) is one of the major constituents imparting pungency to pepper. It exhibits 
diverse pharmacological activities like anti-oxidant, anti-tumor, anti-inflammatory, 
immuno-modulatory, anti-apoptotic and anti-metastatic activities[23]. 
 
Fig 4.6: Structure of piperine 
 
a. Anti-oxidant activity 
Inflammation leads to the production of free radicals and generates inflammatory 
response factors like Interleukin-6 which help in increasing tumour development. 
Piperine was found to decrease the amount of superoxide ions (O2–) and hydroxyl radicals 
(OH•) which are known to injure surrounding tissues and organs in rats fed with a high 
fat diet[24]. It also inhibited the expression of IL-6 and matrix metalloproteinase 13 in rat 
arthritis models[25] which are important factors helping in inflammation.  
b. Immuno-modulatory effects 
Mouse splenocytes were used to evaluate the in-vitro immune-modulation of piperine for 
cytokine production, macrophage activation and lymphocyte proliferation. Piperine 
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treated mouse splenocytes demonstrated an increase in the secretion of Th-1 cytokines 
(IFN-γ and IL-2), increased macrophage activation and proliferation of T and B cells[26].  
c. Apoptotic effect 
Apoptosis is often downregulated in cancer cells to maintain continued proliferation. The 
apoptotic effect of piperine was studied in prostate cancer cell lines wherein treatment 
with piperine induced apoptosis by the activation of caspase-3 and by the cleavage of 
PARP-1 proteins in different prostate cancer cells like PC-3, DU-145 and LNCaP prostate 
cancer cells[27]. 
d. Anti-metastatic effect 
Metastasis is the development of secondary tumours at places other than the site of origin. 
Cells treated with piperine showed a reduction in the expression of cyclin B1 which is 
important for cell cycle progression in the 4T1 breast cancer cell line. Piperine 
significantly decreased the mRNA expression of MMP-9 and MMP-13 which play an 
important role in basement membrane degradation. 4T1 cells are shown to metastasize to 
organs like the lung 10th day following inoculation of 1×105 tumour cells. The extent of 
metastasis in lungs was found to be less in piperine-treated mice as compared to control 
mice as determined by colonogenic assay[28]. 
Piperine has been extensively used as a bioavailability enhancer for other anti-cancer 
drugs, but there is not much research on the anti-cancer activities of piperine alone[29]. 
In this chapter, piperine was encapsulated in chitosan nanospheres by ionic gelation 
method. Mannose was conjugated onto the positively charged amine groups of chitosan 
using EDC-NHS reaction. The release and surface characteristics of this system were 
studied and propose its potential for further anti-cancer work.  
 
4.5. Materials 
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Chitosan, Tween 20, piperine, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
N-hydroxysuccinimide (NHS), N-[tris(hydroxymethyl)methyl]-2-aminoethane sulfonic 
acid (MES) and sodium tripolyphosphate (TPP) were used as received. 
4.6. Methods 
4.6.1. Preparation of nanoparticles 
Piperine encapsulated chitosan nanospheres were made by ionic gelation method as 
explained in the first chapter 1(Section B,I). Briefly, chitosan solution was prepared by 
adding chitosan to a 1% acetic acid solution (pH 4.8) to yield a solution with a 
concentration of 1 mg/mL. The solution was allowed to stir overnight. 10 mL of this 
solution was taken in a beaker. Piperine (5 mg) dissolved in 1 mL acetone was added very 
slowly dropwise, while stirring. This solution was ultrasonicated with a probe sonicator 
at 65% amplitude for 2 minutes. Sodium tripolyphosphate (1 mg/mL) was added 
dropwise to this solution with continuous stirring, and the end point was indicated by a 
slight turbidity. The above solution was allowed to stir for 3 hours for the evaporation of 
the organic solvent and the chitosan encapsulated nanoparticles (P-NP) were collected. 
4.6.2. Determination of the entrapment efficiency 
The entrapment efficiency was calculated by the indirect method. The supernatant was 
collected after centrifugation of the chitosan nanoparticles. The calibration curve of 
piperine at known concentrations was constructed using UV-Visible spectroscopy at its 
absorption maxima of 342 nm. The amount of unloaded piperine was calculated using the 
curve. 
4.6.3. Bioconjugation 
P-NPs were conjugated with mannose using a protocol mentioned in the literature[30,31]. 
Briefly, 10 mg of mannose was allowed to undergo a ring opening reaction by stirring in 
SAB buffer (pH 5) for 1-2 hours. Mannose solution was added to P-NPs and incubated 
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with 15 mg N-hydroxysuccinimide (NHS) and 20 mg N-(3-dimethylaminopropyl)-N-
ethyl carbodiimide hydrochloride (EDC). The mixture was stirred for 4 hours in an inert 
nitrogen environment to allow conjugation to take place.  
Mannose–conjugated chitosan nanoparticles (MP-NPs) were then centrifuged at 10,000 
rpm for 10 minutes to remove unconjugated mannose molecules. The supernatant was 
stored for calculation of the unconjugated peptide. 
4.6.4. Calculation of conjugation efficiency 
Unconjugated mannose was calculated by the phenol-sulphuric acid mannose detection 
method[32]. Briefly, a 5% w/v phenol solution was prepared freshly. 50 µL of unknown 
sample along with known concentrations of mannose solution were added into 96 well 
plate. 150 µL of concentrated sulphuric acid was pipetted into each well and mixed gently, 
followed by the addition of 30 µL of the phenol solution. The plate was covered with 
aluminium foil and allowed to sit for 10 minutes at room temperature. The absorbance 
was now read at 490 nm.  
4.6.5. Physico-chemical characterization 
4.6.5.1.  Particle size and surface charge 
Nanoparticles were optimized for particle size and surface charge. The mean particle size 
and zeta potential of blank nanoparticles (B-NP), piperine loaded nanoparticles (P-NPs) 
and mannose-conjugated nanoparticles (MP-NPs0 were measured by photon correlation 
spectroscopy using a Malvern Zetasizer Nano ZS (Malvern Instrument Ltd., Malvern, 
UK). Samples were diluted 10 times with double distilled water and analyzed at 25 °C 
with a backscattering angle of 173º. 
4.6.5.2.  FTIR analysis 
FTIR analysis of B-NPs, P-NPs and MP-NPs was carried by using an IR 
spectrophotometer (Perkin Elmer, USA). Pellets were prepared by adding approximately 
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3 mg of the sample to 100 mg of KBr. Samples were scanned in an inert atmosphere in 
the range of 400–4000 cm−1. 
4.7. Results 
4.7.1. Preparation of nanoparticles 
Piperine-encapsulated chitosan nanoparticles were prepared by ionic gelation method as 
explained in Chapter 1. The end of nanoparticle formation was noted as slight turbidity. 
The formulation was optimized for sodium tripolyphosphate (TPP) added which was in 
the range of 1-3 mg.  An amount of 2.5 mg TPP gave a particle size of 163.7 ± 3.4 nm 
and zeta potential of 23.4 ± 2.4 mV (Table 4.4). An increase in the amount of TPP was 
found to cause a decrease in the hydrodynamic size of the nanoparticles. This can be 
hypothesized to the increase in the compactness of the nanoparticle by the increased 
degree of cross-linking. A further increase in the amount of TPP (3 mg) did cause a 
reduction in particle size. However, the surface potential of the particles could not record 
a stable value. Hence, formulation F4 was carried forward for further optimization. The 
formulation was also optimized for total volume of chitosan solution. Volumes of 8, 10 
and 12 mL gave a particle size of 157.9 ± 2.8 nm, 163.7 ± 3.7 nm and 341.1 ± 4.3 nm, 
respectively. Although particle size was lower in formulation F7 (8 mL), the zeta potential 
could not be recorded which suggested instability in charges. Formulation F4 (10 mL), 
showed adequate particle size and surface potential values and hence, was used for further 
studies. This formulation was also optimized for process parameters such as sonication 
amplitudes and stirring times but the results were constant. Therefore, the same 
parameters as the followed protocol were used for further formulations.  
Table 4.4: Optimization of formulation parameters for the piperine loaded chitosan nanoparticles 
prepared by the ionic gelation method 
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Form
ulatio
n 
Parameter Value Particle size 
(nm) 
Polydispersity 
index 
Zeta 
potential 
(mV) 
F1 Amount of  1 467.4 ± 5.4 0.614 ± 0.2 NR 
F2 TPP 1.5 412.5 ± 3.2 0.468 ± 0.3 NR 
F3 (mg) 2 257.4 ± 2.1 0.428 ± 0.4 27.1± 1.4 
F4 
 
2.5 163.7 ± 3.4 0.345 ± 0.1 23.4±2.4 
F5 
 
3 121.3 ± 3.8 0.254 ± 0.3 NR 
F6 Total Volume 12 341.1 ± 4.3 0.475 ± 0.2 25.8 ± 3.5 
F4 of Chitosan 10 163.7 ± 3.7 0.345 ± 0.1 23.4±2.4 
F7 (mL) 8 157.9 ± 2.8 0.513 ± 0.2 NR 
   *NR- not recorded 
 
4.7.2. Determination of entrapment efficiency 
Formulation F4 was used to determine appropriate drug loading concentrations and 
examine the entrapment efficiency. A calibration curve of known concentrations of 
piperine was constructed using UV-Visible spectroscopy at the λmax of 342 nm. The 
solubility of piperine is low in water and hence, a 1:1 water-ethanol mixture was used to 
make the standard solutions and also the reference. The amount of piperine encapsulated 
was optimized between 1, 3 and 5 mg as beyond this amount, piperine reached its 
solubility limit. Particle sizes were found to increase with an increase in the amount of 
the drug, which could again be attributed to the increased drug dispersion in the lipid 
matrix therefore causing an increase in particle size. The particle sizes for 1, 3 and 5 mg 
were found to be 153.27 ± 2.8 nm, 163.7 ± 3.7 nm and 234.21 ± 5.7 nm, respectively. An 
abrupt increase of particle size at 5 mg piperine (Formulation F9) could be attributed to 
the reducing solubility therefore causing disturbances in the process of nanoparticle 
polymerization. Also, the surface potential for this formulation could not be recorded 
again possibly pointing to an irregularly distributed lipid surface. The F8 formulation (1 
mg) did show lesser particle size and  a good entrapment efficiency of 78.2 ± 2.7%. 
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However, the F4 (3 mg) formulation was chosen as even with a lesser entrapment 
efficiency (75.3 ± 4.3%), more drug (~ 2.25 mg)will be loaded in the formulation. 
        
                                         
Fig 4.7: Calibration curve of piperine 
 
 
Table 4.5: Optimization of encapsulation of piperine and entrapment efficiency in piperine loaded 
chitosan nanoparticles (P-NP) 
 
 
4.7.3. Bioconjugation 
Bioconjugation with mannose was carried out as mentioned in the protocol (Section 
3.3.3.). Ring opening of mannose was carried out by using acidic SAB buffer at pH 5 to 
allow ligand conjugation. The conjugation occurs by formation of a Schiff’s base (–
N=CH–) between the aldehyde group of the mannose and the primary amine groups of 
the chitosan.  Schiff’s base could get reduced to the secondary amine (–NH–CH2–) and 
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name 
Parameter  Type Particle size 
(nm) 
Polydispersit
y 
index 
Zeta 
potential 
(mV) 
Entrapment 
efficiency 
(%) 
F8 Amount  1 153.27 ± 2.8 0.203 ± 0.2  -24.4±1.13 78.2 ± 2.7 
F4 of Drug   3 163.7± 3.7 0.345± 0.1 23.4±2.4 75.3 ± 4.3 
F9 (mg)  5 234.21 ± 5.7 0.664 ± 0.3 NR 62.4 ± 3.4 
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remain in equilibrium with the Schiff’s base[31]. The mannose conjugated chitosan 
nanoparticles were washed thrice by centrifugation with MilliQ water to remove unbound 
mannose. The pellet was stored for further studies. 
4.7.4. Calculation of conjugation efficiency 
The conjugation efficiency of the mannose to the MgF-SLNs was evaluated by the 
phenol-sulphuric acid assay for the detection of sugars. The method works on the 
principle of reaction of the aulphonated phenol with the sugars in a solution to give rise 
to a yellow orange coloured furfural compound with an absorption maxima at around 490 
nm[32]. The supernatant collected post centrifugation of the MP-NPs was used to 
determine the unconjugated mannose. The unknown mannose in the supernatant was 
determined by using the standard mannose calibration curve. The conjugation efficiency 
after using 10 mg of mannose was found to be 92.34 ± 3.31%. 
4.7.5. Physico-chemical characterization 
4.7.5.1. Particle size and surface charge 
The particle size and surface charge of blank nanoparticles (B-NP), piperine-loaded P-
NP and conjugated MP-NP nanoparticles were observed by a Malvern Zetasizer Nano 
ZS. The particle size of B-NP, P-NP and MP-NP were 152.9 ± 2.8 nm, 163.7 ± 3.7 nm 
and 196.4 ± 4.2 nm, respectively (Table 4.6 and Fig. 4.8). There is an increase of about 
10 nm in particle size from B-NP to P-NP which could be attributed to the packing of 
piperine molecules between the chitosan polymer matrix therefore leading to increase in 
size. The zeta potential for B-NP and P-NP were 24.1 ± 2.3 and 23.4 ± 2.4 mV, 
respectively, with the positive potentials due to the amine groups present in chitosan. This 
also suggests that there was no change in surface properties suggesting that piperine was 
encapsulated and not adsorbed onto the particle surface. The particle size of MP-NP is 
196.4 ± 4.2 nm, which is more compared to P-NP (163.7± 3.7). This could be due to the 
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attachment of mannose to the surface and hence an increase in the overall particle 
diameter. Also, the zeta potential of MP-NP is found to reduce to 16.3 ± 3.2 mV from a 
more positive 23.4 ± 2.4 mV in P-NP. This could be due to the attachment of mannose to 
the nanoparticle surface, engaging the positive amino groups in chitosan. The negatively 
charged alcohol groups (OH-) on the ring-opened mannose could also contribute 
additional negative charges to bring down the zeta potential to a less positive value. 
 
Table 4.6: Particle size distribution, polydispersity and zeta potential values for the blank 
formulation (B-NP), piperine-loaded nanoparticles (P-NP) and mannose-conjugated (MP-NP) 
formulations determined by dynamic light scattering 
 
 
 
 
 
 
 
 
 
 
Formulation 
name 
Particle size 
(nm) 
Polydispersity 
index 
Zeta 
potential 
(mV) 
B-NP 152.9 ± 2.8 0.269 ± 0.2 24.1 ± 2.3 
P-NP 163.7± 3.7 0.196 ± 0.4  23.4 ± 2.4 
MP-NP 196.4 ± 4.2 0.345± 0.1 16.3 ± 3.2 
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Fig 4.8: Particle size distribution for blank formulation (B-NP), piperine-loaded nanoparticle (P-
NP) and mannose-conjugated (MP-NP) formulations measured by dynamic light scattering 
4.7.5.2. FTIR Analysis 
FTIR analysis was carried out for B-NP, P-NP, MP-NP and pure piperine (Fig 4.9). 
Characteristic peaks of chitosan for O-H stretching frequency between 3200-3400 cm-1 
were observed in both B-NP (3424 cm-1) and P-NP (3388 cm-1). Peaks for N-H bending 
(amine) appear at 1570 cm-1 and 1415 cm-1 for B-NP. P-NP also shows N-H bending 
peaks at 1567 cm-1 and 1384 cm-1. The similarity in spectra between B-NP and P-NP 
suggests that no unfavourable interactions took place between piperine and the chitosan 
matrix. Piperine shows its characteristics peaks at 2925 cm-1 for C–H stretching vibration 
and 1638 cm-1 for C-C stretching vibration. MP-NP shows broad and intense O–H stretch 
B-NP P-NP 
MP-NP 
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and C–O stretch peaks of mannose around 3462 cm-1 and 1094 cm-1, respectively. The 
N–H deformation of secondary amine at 1417 cm-1 confirmed the Schiff’s base formation, 
and the amide linkage formed between the aldehyde of mannose and the amine 
termination of chitosan was also observed at 1640 cm-1. These results suggest successful 
conjugation between the mannose molecules and chitosan nanoparticle surfaces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 4.9: Fourier transform infrared (FTIR) spectra for blank formulation (B-NP), piperine-loaded 
chitosan formulation (P-NP), piperine and mannose-conjugated chitosan (MP-NP) formulations 
 
4.8. Conclusions  
In summary, solid lipid nanoparticles encapsulating mangiferin showed good size and 
surface potential for application in cancer theray. Conjugation for bombesin was carried 
out to rovide sppecificity towards cancers overexpressing GRPR recetors. FTIR studies 
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showed formation of amide bond linkages between SLNs and bombesin. Thus, this 
system could be a strong candidate for cancer drug delivery. Mannose conjugated 
chitosan nanoparticles encapsulating piperine and mangiferin-encapsulated SLNs are 
both promising candidates for futher anti-cancer studies based on their physicochemical 
properties. These two systems can be used to study in-vitro and in-vivo efficacy in future 
studies.  
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Summary and future perspectives 
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Cancer remains one of the world’s most debilitating diseases with 8.8 million deaths 
worldwide in 2015, with the number of new cases expected to rise by 70% in the next 
two decades[1].  
Drug delivery in cancer mainly uses two types of approaches; passive and active 
targeting[2]. Passive targeting relies on the distinct properties of tumour tissue (such as 
enhanced permeation and retention effect) for delivery of the therapeutic payload. 
Increased interendothelial gaps in tumour blood vessels causes increased penetration of 
nanoparticles up to a size of 400 nm, with defective lymphatic drainage leading to 
improved retention and, therefore, more delivery of cytotoxic drugs at tumour sites[3].  
The rationale of this thesis is the preparation of nanoparticle assemblies for cancer therapy 
with reduced non-specific toxicity. Many conventional model drugs for cancers lead to 
non-specific associated toxicities at other sites, creating undesirable side effects[4]. 
Phytochemicals were used as cancer therapeutics in this thesis, which are plant-derived, 
naturally occurring compounds. Epigallocatechin gallate (EGCG), mangiferin and 
piperine are derived from green tea, mango and pepper, respectively. All of these 
compounds have shown anti-cancer potential in-vitro[5–7]. These compounds have been 
part of the regular human diet for centuries, and hence have mechanisms in place for their 
effective metabolism, thus leading to reduced injury to non-targeted sites. 
Two types of nanoparticle vehicles have been explored in this thesis viz. solid lipid 
nanoparticles and chitosan nanoparticles. Solid lipid nanoparticles are made of a lipid 
matrix which is solid at room temperature. The solid core gives added protection to the 
encapsulated drugs. Also, these lipids can be broken down within the cells by metabolic 
enzymes such as lipases. This helps to circumvent accumulation-induced toxicity which 
is one of the major drawbacks associated with nanoparticle delivery[8]. Solid lipid 
nanoparticles have also been known to show controlled release of the drugs from the 
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matrix and thus, improved bioavailability and sustained efficacy[9]. Chitosan 
nanoparticles have a matrix of covalently cross-linked chitosan molecules. Chitosan is a 
naturally occurring polysaccharide extracted from the shells of crabs. The cross linked 
polymer also helps in effective encapsulation and increased bioavailability of the 
encapsulated drugs within the biological system[10]. These nanoparticles can also be 
easily degraded within the biological system and thus do not lead to accumulation[11]. 
Both the targeting approaches (active and passive) were explored in this study. Passive 
targeting was used in Chapter 2 wherein EGCG was encapsulated in SLNs and studied 
the effect of encapsulation on the anti-cancer efficacy. Other targeting ligands have been 
used in the following chapters, including bombesin which is a tetra-decapeptide isolated 
from the toad Bombina bombina. Bombesin is an amphibian analogue of the mammalian 
gastrin releasing peptide which is a natural ligand to gastrin releasing peptide receptors, 
overexpressed in a variety of cancers and hence used as a tumour marker[12]. The 
mechanism of nanoparticle uptake through GRPR binding is via receptor mediated 
endocytosis. Mannose was used as a ligand to target lectin receptors which are commonly 
overexpressed in lung, liver, breast and brain tumours. Uptake of nanoparticles in this 
case is also via receptor mediated or clathrin-mediated endocytosis. 
EGCG is the most abundant catechin found in green tea. It has been explored in recent 
times for its anti-cancer activity[13]. The structure of EGCG however causes it to be 
easily degraded within the cell[14]. It has 8 free hydroxyl groups which can be easily 
acted upon by cellular enzymes, causing it to be glucuronidated, sulphonated or amidated 
therefore causing a loss in activity[14]. 
The stability of EGCG with different pH conditions using buffer solutions was initially 
studied. EGCG was found to be most stable in acidic pH with stability increasing as the 
solution becomes increasingly acidic. However, stability was found to reduce as we move 
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towards the neutral pH and further is found to degrade almost instantly in basic solutions. 
Therefore, to combat stability issues EGCG was encapsulated in solid lipid nanoparticles. 
Furthermore, the physico-chemical parameters such as particle size and surface charge of 
the ECG-encapsulated SLNs were studied. Surface functionalities was studied using 
FTIR spectroscopy to study any changes in the SLN surface post encapsulation. Spectra 
showed encapsulation of EGCG as opposed to adsorption. Also, DSC studies were carried 
out to further test whether EGCG was encapsulated within SLNs. The crystalline melting 
peak of EGCG was not seen in the EGCG-encapsulated in SLNs, which therefore 
confirms that EGCG was not present in its bulk state.  Drug release studies were 
performed to determine the release characteristics of EGCG from the SLNs. The results 
indicated sustained release in acidic pH which could demonstrate favourable release in 
acidic tumour tissue. Colloidal stability of the nanoparticles was studied in different 
physiological mediums such as PBS, DW and serum to check the behaviour of the 
nanoparticles in biological mimicking environments, wherein EGCG-SLN showed 
stability in both serum and PBS and high resistance to electrolyte-induced aggregation. 
Finally, in-vitro cytotoxicity was employed to assess the change in anti-cancer efficacy 
post encapsulation. EGCG-SLN showed an 8-fold increase in cytotoxicity in the breast 
cancer cell line and a 4-fold increase in cytotoxicity in the prostate cancer cell line as 
opposed to pure EGCG. It also showed enhanced apoptosis as opposed to the free drug. 
EGCG-SLN also showed more apoptosis in both cell lines as opposed to pure EGCG. 
Thus, we can conclude that the increase in anti-cancer efficacy was obtained owing to the 
encapsulation of EGCG within SLNs.    
Bombesin-targeted solid lipid nanoparticles were prepared by the double-emulsification 
solvent evaporation method as shown in Chapter1 followed by conjugation with the 
peptide by EDC-NHS reaction. Bombesin was used as a ligand to target the gastrin-
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releasing peptide receptor which is overexpressed in breast cancer[15]. FTIR analysis 
validated the formation of an amide bond between the carboxylic COO- of the lipid with 
the free amino group of the peptide. In-vitro studies in breast cancer cell line MDA-MB-
231 as it shows increased expression of GRP receptors were carried out. IC50 values 
indicate that the pure drug EGCG has low cytotoxicity in MDA-MB 231, but its activity 
increased more than 8 times after encapsulation in SLNs and more than 14 times post 
conjugation with bombesin. Fluorescence uptake images show more uptake in RB-SLN 
compared to non-targeted R-SLN at all time points. Migration studies show substantial 
inhibition by the targeted EB-SLN formulation. Survival studies on C57BL6 mice 
showed greater survival in mice administered with the targeted formulation compared to 
the non-targeted ones, which was in turn more than mice administered with only EGCG. 
Reductions in tumour volumes in mice administered with targeted formulations were also 
observed. This study shows the potential of bombesin conjugated formulation in efficient 
breast cancer therapy. 
Mangiferin and piperine are two phytochemicals which have been used in ancient 
medicine for their medicinal properties including their anti-cancer activities. Although 
their mechanisms of action have been widely explored and documented, the number of 
formulations that have been tried with these phytochemicals is comparatively low. In this 
work, two novel systems for the delivery of these phytochemicals have been explored. 
Mangiferin was encapsulated in solid lipid nanoparticles by a single-emulsification 
method and further conjugated with bombesin, which is an efficient ligand for targeting 
that was explored in Chapter 3. In this work, the formulation was optimized for particle 
size and surface potential and checked for its physicochemical characteristics. Fourier 
transform infrared analysis showed successful conjugation between the stearic acid 
carboxylic group in SLNs and amine group in bombesin. For piperine, a chitosan 
  
  154 
 
formulation was tested to optimise a nano-formulation with a carbohydrate matrix. 
Mannose was conjugated onto this nanoparticle for targeting towards lectin receptors. 
Zetasizer measurements showed size dimensions of <160 nm and surface charge values 
of approximately 24mV. FTIR showed successful conjugation and there were no 
incompatibilities between piperine and the excipients used for the nanoparticle system. 
Both systems show good promise for further studies representing exciting candidates for 
further in-vitro and in-vivo studies. 
 Future prospective in this work: 
 EGCG-SLN formulation showed 8 times more cytotoxicity than EGCG in breast 
cancer cell lines MDA-MB 231 and 4 times more than EGCG in DU-145 prostate cancer 
cell lines. In-vivo studies such as biodistribution and pharmacokinetics can be carried out 
to further study the efficacy of encapsulated system compared to free EGCG. 
 A surprising observation was the differential cytotoxicities of the EGCG 
formulations in cancerous and non-cancerous cell lines. EGCG showed more cytotoxity 
in non-cancerous cell lines as compared to cancerous cell lines. These findings suggest 
differential specificity of the conjugated system which could be a superior advantage if 
sufficiently validated. More work remains to be done in this respect. Work on in-vivo 
studies with this system such as pharmacokinetic studies and tissue distribution can be 
carried out to determine in-vivo efficacy. 
 Mannose conjugated chitosan nanoparticles encapsulating piperine and mangiferin-
encapsulated SLNs conjugated with bombesin are both promising candidates for futher 
anti-cancer studies based on their physicochemical properties. These two systems can be 
used to study in-vitro cancer efficacy by cytotoxicity, uptake and apoptosis assays. In-
vivo studies such as pharmacookinetics can be carried out to determine distribution of 
these nanoparticle system in-vivo. 
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Key knowledge additions provided by this thesis: 
➢  EGCG-loaded SLNs helped improve the stability of a labile polyphenol such as 
EGCG which has pH dependent stability issues. The increase in in-vitro efficacy could 
be attributed to the additional stability imparted by the lipid core and also the slow release 
from the SLN.  
➢ EGCG-loaded SLNs conjugated with bombesin showed greater efficacy in-vitro as 
well as in-vivo when compared to non-targeted nanoparticles. In-vitro studies have shown 
specificity to cancerous cell lines in comparison to non-cancerous cells. Survival studies 
showed greater survival of mice injected with targeted formulations.  
➢ Piperine and mangiferin remain to be explored as potent chemotherapeutics in a 
targeted system. SLN formulation with mangiferin and chitosan formulation with 
piperine were optimized for size and charge parameters. The conjugation reactions 
with bombesin and mannose were validated by FTIR analysis. Thus, two novel 
nanoparticle systems have been optimized for particle size, surface conjugation and 
surface potential in this thesis.  
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